{"gene":"VAV3","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":1999,"finding":"Vav3 functions as a GDP-GTP nucleotide exchange factor for RhoA, RhoG, and (to a lesser extent) Rac1; it binds physically to the nucleotide-free states of these GTPases. This activity is stimulated by tyrosine phosphorylation and becomes constitutively active upon deletion of the calponin-homology (CH) region. The DH and ZF domains are both essential for GTPase binding and activation, with the ZF region working coordinately with the catalytic DH region.","method":"Nucleotide exchange assays, physical binding assays, deletion/loss-of-function mutagenesis, actin cytoskeleton readouts in transfected cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro exchange assays combined with domain mutagenesis and multiple orthogonal functional readouts in a single foundational study","pmids":["10523675"],"is_preprint":false},{"year":1999,"finding":"Expression of activated (N-terminally truncated) Vav3 induces actin relocalization, stress fibers, lamellipodia, membrane ruffles, and cytokinesis defects (binucleated cells), requiring only the DH-PH-ZF central region and not the C-terminal SH3-SH2-SH3 domains.","method":"Truncation mutant overexpression, fluorescence microscopy of actin cytoskeleton, cytokinesis assay in transfected cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — domain dissection with multiple cytoskeletal readouts, replicated in subsequent studies","pmids":["10523675"],"is_preprint":false},{"year":2000,"finding":"Vav3 interacts with and is tyrosine-phosphorylated downstream of multiple receptor protein tyrosine kinases (EGFR, Ros, insulin receptor, IGF-IR); it also associates with downstream signaling molecules Shc, Grb2, PLC-γ, and PI3K. Overexpression activates Rac1 and Cdc42, while N-terminal truncation (removing CH and acidic domains) activates RhoA and Rac1 but loses Cdc42 activation.","method":"Yeast two-hybrid, co-immunoprecipitation, in vitro GST-fusion binding assays for active GTPases, transfection in 293T and NIH 3T3 cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple binding assays, GTPase activation assays, domain mutagenesis, replicated across labs","pmids":["11094073"],"is_preprint":false},{"year":2002,"finding":"Vav3 expression is cell-cycle regulated, being transiently up-regulated during mitosis in HeLa cells. Enforced Vav3 expression perturbs cytokinesis and produces multinucleated cells in a RhoA-dependent manner requiring phosphorylation of the regulatory tyrosine Y173.","method":"Cell cycle synchronization, Western blot, enforced expression, RhoA dependence assay, dominant-negative and phosphorylation-site mutant analysis","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean cell-cycle and loss-of-function experiments with mutagenesis of the key regulatory tyrosine","pmids":["11917103"],"is_preprint":false},{"year":2002,"finding":"Vav3-induced cell transformation (focus formation) requires PI3K/Akt signaling, Rac1, RhoA, and Cdc42, but PI3K/MAPK inhibition does not affect cytoskeletal (lamellipodia/filopodia) changes. Cell motility enhancement depends on PI3K, Rac1, and Cdc42 but not RhoA.","method":"Focus-formation assays, pharmacological inhibition of PI3K/MAPK, dominant-negative GTPase constructs, cell motility assays in NIH 3T3 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — epistasis via dominant-negative constructs and pharmacological inhibitors with multiple orthogonal readouts","pmids":["11884391"],"is_preprint":false},{"year":2002,"finding":"The adaptor protein APS binds the N-terminal CH (autoinhibitory) domain of Vav3. This interaction is stabilized by Lck-mediated tyrosine phosphorylation of Vav3, and APS in turn enhances Lck-mediated Vav3 phosphorylation. APS binding to the PH domain of APS–Vav3 CH domain interaction relieves autoinhibition and increases Vav3 transforming activity.","method":"Co-immunoprecipitation, GST pulldown, focus-formation assays, domain mutant analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding and functional assays in single lab","pmids":["12400014"],"is_preprint":false},{"year":2002,"finding":"In B cells, Vav3 promotes sustained PIP3 production via Rac1 activation of PI3K, downstream of BCR engagement. Loss of Vav3 attenuates PIP3 generation, calcium mobilization, and JNK activation; these defects are rescued by deletion of the PIP3 phosphatase SHIP.","method":"B cell line Vav3 knockout, dominant-negative Rac1 expression, PI3K activity assay, PIP3 measurement, SHIP deletion rescue","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function, biochemical pathway rescue, multiple readouts confirming pathway position","pmids":["11805146"],"is_preprint":false},{"year":2004,"finding":"Vav1 and Vav3 have redundant roles in activating PLCγ2 downstream of the ITAM-coupled collagen receptor GPVI in platelets. Single Vav3 knockout shows normal GPVI response; Vav1/Vav3 double knockout markedly inhibits aggregation, spreading, and PLCγ2 tyrosine phosphorylation upon GPVI stimulation.","method":"Single and double gene knockout in mice, platelet aggregation assay, spreading assay, Western blot for PLCγ2 phosphorylation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic epistasis with double knockout and multiple functional platelet readouts","pmids":["15456756"],"is_preprint":false},{"year":2005,"finding":"Vav3 is essential for stimulated osteoclast activation in vivo: Vav3-deficient osteoclasts display defective actin cytoskeleton organization, polarization, spreading, and bone resorption due to impaired signaling downstream of M-CSF receptor and αvβ3 integrin. Genetic and biochemical evidence places Syk tyrosine kinase as a crucial upstream regulator of Vav3 in osteoclasts.","method":"Vav3 knockout mice, bone density measurement, osteoclast functional assays, Syk genetic and biochemical epistasis, co-immunoprecipitation","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout with bone density phenotype, biochemical pathway placement, multiple orthogonal methods","pmids":["15711558"],"is_preprint":false},{"year":2005,"finding":"During NGF-stimulated neurite outgrowth in PC12 cells, local PIP3 accumulation recruits Vav2 and Vav3 to activate Rac1 and Cdc42. Vav2/Vav3 are required for a positive feedback loop between PI3K and Rac1/Cdc42 that drives localized protrusions; RNAi depletion of Vav2 and Vav3 significantly inhibits Rac1/Cdc42 activation and neurite formation.","method":"FRET biosensors, RNAi knockdown, live-cell imaging of PIP3 and GTPase activity in PC12 cells","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — FRET activity imaging plus RNAi knockdown with multiple functional readouts in a single rigorous study","pmids":["15728722"],"is_preprint":false},{"year":2005,"finding":"TCR-induced membrane translocation and immunological synapse (IS) recruitment of Vav3 requires its SH2 domain-mediated association with SLP-76. Vav3 mutants with disabled SH2 (R697L) or lacking SH3-SH2-SH3 domains fail to bind SLP-76 and do not translocate. Membrane localization depends on upstream signaling via Lck, ZAP-70, LAT, and SLP-76. Vav3 is required for NFAT activation in T cells lacking Vav1.","method":"Subcellular localization imaging (membrane/IS), Vav3 mutant expression, co-immunoprecipitation with SLP-76, signaling-deficient cell lines (Lck−/−, ZAP-70−/−, LAT−/−, SLP-76−/−), NFAT reporter assay, Vav3 knockdown in Vav1-deficient T cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including domain mutagenesis, deficient cell lines, and localization/functional assays","pmids":["15708849"],"is_preprint":false},{"year":2005,"finding":"Single-particle electron microscopy resolved the structures of inactive (unphosphorylated), active (tyrosine-phosphorylated), and constitutively active (N-terminally deleted) Vav3. Tyrosine phosphorylation induces global conformational rearrangements; the phosphorylated and N-terminally deleted forms have distinct conformations, indicating that constitutive oncogenic activity is structurally more complex than simple relief of autoinhibition.","method":"Single-particle electron microscopy, structural comparison of three functional states","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural method with functional state comparison, single lab but rigorous EM-based analysis","pmids":["15775967"],"is_preprint":false},{"year":2005,"finding":"Vav3 potentiates androgen receptor (AR) transcriptional activity in a GEF-independent but pleckstrin homology (PH) domain-dependent manner. Vav3 does not directly interact with AR and does not increase AR protein levels; enhancement of AR activity requires the AR N-terminal activation function 1 (AF1).","method":"Reporter gene assays, Vav3 knockdown, domain deletion mutants, co-immunoprecipitation (negative result for direct AR interaction)","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assays with domain dissection, single lab; direct binding was negative","pmids":["16384856"],"is_preprint":false},{"year":2006,"finding":"Vav3 deficiency in mice causes tachycardia, systemic hypertension, and cardiovascular remodeling via sympathetic neuron hyperactivity from birth, leading to elevated catecholamines, renin-angiotensin system activation, and progressive loss of cardiovascular homeostasis. Pharmacological studies confirmed the causative hierarchy of sympathetic → renin-angiotensin events.","method":"Vav3 knockout mice, blood pressure and heart rate measurement, catecholamine assays, pharmacological blockade of sympathetic and renin-angiotensin systems","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout with pharmacological rescue establishing pathway hierarchy","pmids":["16767097"],"is_preprint":false},{"year":2006,"finding":"Vav3 is overexpressed in androgen-independent prostate cancer; its DH domain is responsible for AR activation. Vav3 overexpression activates AR via the PI3K-Akt pathway; PI3K inhibitors or dominant-negative Akt attenuate this effect, and PI3K co-transfection enhances it.","method":"siRNA knockdown, overexpression, AR luciferase reporter assay, PI3K inhibition, dominant-negative Akt, Western blot for pAkt","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple signaling assays with domain dissection, single lab","pmids":["16762975"],"is_preprint":false},{"year":2007,"finding":"In NPM-ALK+ anaplastic large cell lymphoma, Vav3 is activated by NPM-ALK and mediates Rac1 activation downstream. Vav3 associates with NPM-ALK via its SH2 domain binding to phospho-Y343 of NPM-ALK, forming a complex with pp60c-src and Lyn. Src kinases control Vav3/Rac1 stimulation. Vav3-specific shRNA and dominant-negative Rac1 inhibit NPM-ALK-induced cell motility and invasion.","method":"Co-immunoprecipitation, domain mutant analysis (SH2-disabled), shRNA knockdown, dominant-negative Rac1, motility/invasion assays, phospho-Vav3 in patient biopsies","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, domain mapping, shRNA loss-of-function, and in vivo patient biopsy validation in a single study","pmids":["17998938"],"is_preprint":false},{"year":2008,"finding":"Vav3 complexes physically with ERα (demonstrated by GST pulldown). The DH domain of Vav3 is essential for ERα activation. Vav3 activates ERα partly via the PI3K-Akt pathway and stimulates breast cancer cell growth.","method":"GST pulldown, luciferase reporter assay, siRNA knockdown, PI3K inhibition, domain deletion analysis","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — GST pulldown for physical interaction plus functional reporter assays with domain dissection, single lab","pmids":["18518979"],"is_preprint":false},{"year":2009,"finding":"AhR directly regulates constitutive Vav3 mRNA expression in a ligand-independent manner by binding to the vav3 promoter. In AhR-null fibroblasts, reduced Vav3 expression leads to decreased Rac1 activity, increased RhoA/ROCK pathway activation, enlarged cell area with increased F-actin stress fibers, depolarized focal adhesions, and enhanced spreading/adhesion. Re-expression of AhR or Vav3 restores wild-type morphology.","method":"ChIP of AhR at vav3 promoter, AhR-/- and Vav3-/- MEFs, pharmacological Rac1/ROCK inhibition, siRNA knockdown of Vav3, GTPase activity assays, cell morphology and adhesion assays","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP confirms transcriptional regulation; multiple genetic and pharmacological rescue experiments with orthogonal readouts","pmids":["19158396"],"is_preprint":false},{"year":2010,"finding":"Aryl hydrocarbon receptor (Ahr) controls Vav3 expression in kidney, lung, heart, liver, and brainstem in a ligand-independent manner. Ahr-/- and Vav3-/- mice share phenotypes of hypertension, tachypnea, and sympathoexcitation, with Ahr-/- mice also showing GABAergic transmission defects in the ventrolateral medulla present in Vav3-/- mice.","method":"Ahr-/- and Vav3-/- mouse phenotypic comparison, tissue Vav3 expression analysis, Ahr ligand treatment, cardiorespiratory and autonomic measurements","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — parallel genetic knockout comparison in multiple tissues with overlapping phenotypes establishes in vivo pathway hierarchy","pmids":["21115475"],"is_preprint":false},{"year":2011,"finding":"Vav3 localizes to both cytoplasm and nucleus; nuclear localization depends on the PH domain. Membrane targeting of Vav3 abolishes its potentiation of AR activity, while nuclear targeting of a PH mutant rescues AR coactivation. Sequential ChIP shows Vav3 and AR are co-recruited to the same AR target gene enhancer complexes. Vav3 strongly stimulates AR N-terminal–C-terminal (N-C) interaction required for maximal AR transcriptional activity.","method":"Subcellular fractionation, fluorescence localization, membrane/nuclear targeting constructs, sequential ChIP (re-ChIP), N-C interaction assay, luciferase reporter assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP and re-ChIP combined with localization experiments and multiple functional assays in a single study","pmids":["21765461"],"is_preprint":false},{"year":2012,"finding":"Vav3 physically interacts with AR splice variant AR3 (AR-V7) as shown by co-immunoprecipitation. Vav3 potently enhances transcriptional activity of AR3 and ARv567es, and promotes nuclear accumulation of AR3. Vav3 or AR3 knockdown greatly reduces CRPC cell proliferation and ligand-independent AR activity.","method":"Co-immunoprecipitation, nuclear/total AR3 fractionation, siRNA knockdown, luciferase reporter assay, soft agar colony formation","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus functional assays with knockdown, multiple orthogonal readouts","pmids":["23023561"],"is_preprint":false},{"year":2012,"finding":"Vav3 deficiency delays p190-BCR-ABL-driven B-cell lymphoblastic leukemogenesis and phenocopies Rac2 deficiency (a downstream effector), establishing Rac2 as a downstream effector of Vav3 in this context. Vav3 deficiency induces apoptosis of leukemic progenitors with decreased RhoGTPase/PAK activation, increased Bad phosphorylation, and upregulation of Bax, Bak, and Bik. Vav3 activity is only partly ABL TK-dependent, and Vav3 deficiency collaborates with TKIs to inhibit CrkL activation.","method":"Vav3 knockout and Vav1/Vav2-deficient mouse models, BCR-ABL leukemogenesis assay, apoptosis assays, GTPase activation assays, TKI combination studies in vitro and in vivo","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with multiple knockouts, biochemical pathway analysis, in vivo leukemogenesis model","pmids":["22692505"],"is_preprint":false},{"year":2012,"finding":"EphA2 stimulation by ephrinA1 recruits and tyrosine-phosphorylates Vav3, leading to Rac1 activation and increased prostate cancer cell migration and invasion. Reduction of Vav3 decreases para-aortic lymph node and bone metastasis in vivo.","method":"Receptor stimulation, co-immunoprecipitation, Rac1 activity assay, Vav3 knockdown, in vivo metastasis model","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and GTPase assay with in vivo validation, single lab","pmids":["22659453"],"is_preprint":false},{"year":2012,"finding":"Co-chaperone Cdc37 was identified as a Vav3-interacting protein by yeast two-hybrid and confirmed by GST pulldown and co-immunoprecipitation. Cdc37 potentiates Vav3 co-activation of AR transcriptional activity and enhances AR N-C interaction. Disruption of Vav3-Cdc37 interaction inhibits Vav3 enhancement of AR activity and reduces prostate cancer cell proliferation in Vav3-expressing cells. Cdc37 does not affect Vav3 nucleotide exchange activity, protein levels, or subcellular localization.","method":"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, AR reporter assay, AR N-C interaction assay, cell proliferation assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple binding assays plus functional validation, single lab","pmids":["23281476"],"is_preprint":false},{"year":2014,"finding":"VAV3 depletion comparatively reduces viability of endocrine-therapy-resistant breast cancer cell models. VAV3 expression is selectively reduced upon ERα depletion or by the compound YC-1, placing VAV3 downstream of ERα in endocrine-resistant breast cancer signaling.","method":"shRNA-mediated VAV3 depletion, ERα depletion, viability assays, gene expression analysis","journal":"Breast cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — shRNA loss-of-function with ERα depletion epistasis, single lab","pmids":["24886537"],"is_preprint":false},{"year":2016,"finding":"TRAF6's coiled-coil domain directly interacts with the DH domain of Vav3, forming a complex within the RANK signaling complex independent of the TRAF6 ubiquitination pathway. This TRAF6-Vav3 interaction results from cross-talk between TRAF6-binding sites (T6BSs) and the IVVY motif in the RANK cytoplasmic tail, and enhances downstream NF-κB, MAPK, and NFATc1 activation, thereby inducing osteoclastogenesis.","method":"Proteomic screen for TRAF6-interacting proteins, co-immunoprecipitation, domain-specific interaction mapping, RANK cytoplasmic tail mutants, NF-κB/MAPK/NFATc1 signaling assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — proteomic identification confirmed by Co-IP with domain mapping and multiple functional signaling readouts","pmids":["27507811"],"is_preprint":false},{"year":2017,"finding":"DNMT3B overexpression in HaCaT cells downregulates VAV3 expression via promoter methylation of the VAV3 gene, establishing DNMT3B as a methyltransferase writer that epigenetically represses VAV3.","method":"DNMT3B overexpression, gene expression microarray, promoter methylation analysis","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — epigenetic regulation shown by single method (methylation analysis), single lab","pmids":["28123849"],"is_preprint":false},{"year":2017,"finding":"The atypical C1 domain of Vav3 lacks phorbol ester/diacylglycerol binding (analogous to Vav1) due to specific residues. Engineering phorbol ester binding into the modified Vav3 C1 domain disrupts its guanyl nucleotide exchange activity and causes membrane localization upon phorbol ester treatment, accompanied by altered interactions with other signaling proteins.","method":"Mutagenesis of C1 domain, phorbol ester binding assay, GEF activity assay, subcellular localization analysis, co-immunoprecipitation of signaling partners","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 1–2 / Weak — in vitro GEF assay and mutagenesis plus localization, single lab without replication","pmids":["28927664"],"is_preprint":false},{"year":2018,"finding":"Vav3 is exclusively expressed in microvascular endothelial cells and is associated with a high-resistance barrier phenotype. The barrier-enhancing effect of Vav3 requires its DH domain and downstream activation of Rap1. Vav3 inactivation in vivo increases vascular leakage, establishing Vav3 as a regulator of endothelial barrier stability via DH-domain-dependent Rap1 activation.","method":"Endothelial cell gene expression correlation, ectopic Vav3 expression, DH domain mutant, Rap1 activation assay, barrier resistance measurement, in vivo Vav3 inactivation/vascular permeability assay","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro domain dissection and Rap1 epistasis combined with in vivo vascular permeability phenotype","pmids":["29858212"],"is_preprint":false},{"year":2009,"finding":"Vav3 controls vascular smooth muscle cell (VSMC) proliferation and migration through Rac1/PAK signaling. Vav3 catalytic activity (GEF function) is required for its effect on proliferation; co-expression of dominant-negative Rac1-N17 blocks the proliferative effect. Vav3 overexpression induces Rac1 membrane enrichment and PAK activation.","method":"siRNA silencing screen of 27 Rho GEFs, Vav3 overexpression and catalytic mutant, dominant-negative Rac1, PAK activation assay, proliferation/migration assays, in vivo stented artery model","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional screen, catalytic mutant epistasis, dominant-negative GTPase, and in vivo validation","pmids":["19969623"],"is_preprint":false},{"year":2014,"finding":"Phosphorylation of Tyr426 (equivalent site) in chicken 3BP2 by Syk is required for the inducible interaction of 3BP2 with the SH2 domain of Vav3. Loss of this phosphorylation reduces BCR-mediated Rac1 activation, placing 3BP2-Vav3 interaction as a link between Syk and Rac1 activation.","method":"Mutational analysis of 3BP2 phospho-sites, co-immunoprecipitation with Vav3 SH2 domain, Rac1 activation assay in DT40 B cells","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-directed mutagenesis with functional Rac1 readout, confirmed in chicken B cell model","pmids":["24406398"],"is_preprint":false},{"year":2018,"finding":"In the context of oligodendrocyte biology, Vav3 deficiency accelerates OPC differentiation toward mature oligodendrocytes but reduces myelination capacity; remyelination is impaired in Vav3 knockout cerebellar slices and cuprizone-lesioned mice. FRET biosensors reveal altered RhoA GTPase activation profile in Vav3-deficient oligodendrocytes.","method":"Vav3 knockout mice, OPC differentiation assay, myelination of synthetic microfibers, lysolecithin demyelination of cerebellar slices, cuprizone model, FRET-based Rho GTPase biosensors","journal":"Glia","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple in vitro and in vivo myelination models plus FRET-based mechanistic readout","pmids":["30450647"],"is_preprint":false},{"year":2020,"finding":"ERBB4 interacts with VAV3 via its kinase activity and phosphorylation of Tyr-1022 and Tyr-1162, with the intact VAV3 SH2 domain required for binding. ERBB4 stimulates tyrosine phosphorylation of the VAV3 activation domain (required for GEF activity). Active VAV3 mediates ERBB4-stimulated breast cancer cell migration. VAV1 and VAV2 also co-precipitate with ERBB4.","method":"MS-based interactome analysis, targeted MS, co-immunoprecipitation, ERBB4 kinase mutants, ERBB4 phospho-site mutants, SH2 domain mutant VAV3, dominant-negative VAV3, shRNA knockdown, migration assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — MS identification confirmed by Co-IP, domain mapping with mutagenesis of both partners, and functional migration assays","pmids":["32561640"],"is_preprint":false},{"year":2020,"finding":"Vav3 is apically overexpressed in cystic fibrosis (CF) airway epithelial cells, associates with active β1 integrin luminally exposed, and increases fibronectin deposition. These luminal Vav3/β1-integrin/fibronectin microdomains mediate enhanced Pseudomonas aeruginosa adhesion to the CF epithelium. Vav3 inhibition normalizes fibronectin/β1-integrin expression, improves CF epithelial integrity, and prevents bacterial trapping.","method":"RNA-seq, functional overexpression and siRNA knockdown, co-localization imaging, bacterial adhesion assay, fibronectin/integrin expression analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain- and loss-of-function with mechanistic dissection of β1-integrin/fibronectin complex formation and bacterial adhesion readout","pmids":["32640241"],"is_preprint":false},{"year":2021,"finding":"The small molecule IODVA1 binds directly to VAV3 and inhibits RAC activation and downstream signaling. In Vav3-null cells and animals, IODVA1 shows no activity, confirming VAV3 as its specific target. IODVA1 inhibits BCR-ABL1-driven leukemia cell proliferation and survival in a VAV3-dependent manner, overcoming TKI resistance.","method":"Small-molecule binding to VAV3, Vav3-null genetic control, RAC activation assay, BCR-ABL1 leukemia models in vitro and in vivo, patient-derived xenografts","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct small-molecule binding to VAV3 with null-cell genetic validation and multiple in vitro/in vivo models","pmids":["34711926"],"is_preprint":false},{"year":2022,"finding":"In BCR-ABL B-ALL, Vav3 translocates predominantly to the nucleus where it interacts with BCR-ABL, Rac, and PRC1 proteins Bmi1, Ring1b, and Ezh2. The GEF activity of Vav3 is required for Bmi1-dependent B-cell progenitor self-renewal, nuclear Rac activation, interaction with Bmi1, and mono-ubiquitination of H2A(K119). Mechanistically, nuclear Vav3 prevents Phlpp2-sensitive Akt(S473)-dependent phosphorylation of Bmi1 at S314, which promotes leukemic B-cell progenitor transcriptional reprogramming.","method":"Nuclear fractionation, co-immunoprecipitation of nuclear Vav3 complexes, GEF-dead mutant functional assays, H2AK119Ub ChIP, Akt/Phlpp2/Bmi1 phosphorylation analysis, proliferation and self-renewal assays in Vav3-null leukemia model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (nuclear Co-IP, ChIP, mutagenesis, phosphorylation analysis) establishing a non-canonical nuclear GEF mechanism","pmids":["35650206"],"is_preprint":false},{"year":2023,"finding":"HuR accumulates in the cytoplasm of CF airway epithelial cells, binds to and stabilizes Vav3 mRNA, causing Vav3 overexpression. Disruption of the HuR-Vav3 mRNA interaction improves CF epithelial integrity, inhibits fibronectin-based bacterial docking platforms, and prevents P. aeruginosa adhesion.","method":"RNA-seq, RIP (RNA immunoprecipitation) for HuR-Vav3 mRNA binding, HuR-Vav3 interaction disruption, epithelial integrity and bacterial adhesion assays","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP confirms mRNA-protein interaction; functional rescue provides mechanistic link, single lab","pmids":["36602863"],"is_preprint":false},{"year":2024,"finding":"DDX5 binds VAV3 mRNA and facilitates its N6-methyladenosine (m6A) modification by interacting with the methyltransferase METTL3; m6A-modified VAV3 mRNA is then recognized by IGF2BP1, increasing mRNA stability and VAV3 expression in esophageal squamous cell carcinoma.","method":"RIP for DDX5-VAV3 mRNA binding, METTL3 interaction assays, m6A modification of VAV3 mRNA, IGF2BP1 recognition of m6A-VAV3, mRNA stability assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-protein binding assays and m6A modification cascade, single lab","pmids":["39289531"],"is_preprint":false},{"year":2024,"finding":"STAT3 activation by high-fat diet (HFD) acts as a transcriptional factor to suppress VAV3 expression in liver. VAV3 deficiency retards GLUT4 membrane translocation and impairs glucose homeostasis; VAV3 also participates in cholesterol metabolism in hepatocytes. rAAV8-mediated VAV3 overexpression improves glucose homeostasis and attenuates hepatic cholesterol accumulation in HFD-fed mice.","method":"HFD mouse model, STAT3 transcriptional assay, GLUT4 vesicle trafficking assay, glucose uptake/homeostasis measurements, VAV3 rescue by rAAV8 vector","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo rescue and mechanistic GLUT4 trafficking data, single lab","pmids":["38617550"],"is_preprint":false},{"year":2025,"finding":"Bcl11a directly regulates Vav3 as a downstream transcriptional target in cerebellar Purkinje cells. Conditional Bcl11a deletion reduces Vav3 expression, and Vav3 overexpression partially rescues Purkinje cell dysfunction, dendritic morphology, and abnormal motor/social behaviors in Bcl11a-deficient mice.","method":"Conditional Purkinje cell-specific Bcl11a knockout, Vav3 overexpression rescue, behavioral assays (motor, social), electrophysiology, dendritic morphology analysis","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with rescue experiment demonstrating Vav3 as a functional downstream target of Bcl11a in vivo","pmids":["40855003"],"is_preprint":false},{"year":2025,"finding":"Spleen tyrosine kinase (SYK) promotes Vav3 phosphorylation in osteoclasts; SYK and Vav3 colocalize at the leading edge of osteoclasts. SYK knockdown reduces Vav3 phosphorylation, abolishes SYK/Vav3 enrichment at the leading edge, decreases actin ring formation, and attenuates bone resorption.","method":"Co-localization imaging, SYK knockdown, Western blot for p-Vav3, bone resorption lacunae assay, actin ring formation assay, ACPA+ IgG stimulation of osteoclasts","journal":"Cell biology international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-localization and loss-of-function with multiple osteoclast readouts; single lab, single study","pmids":["40787875"],"is_preprint":false}],"current_model":"VAV3 is a tyrosine phosphorylation-regulated GDP-GTP exchange factor (GEF) that activates RhoA, RhoG, Rac1, and Cdc42 via its catalytic DH domain working cooperatively with the ZF domain; activation is governed by global conformational changes triggered by phosphorylation of a key regulatory tyrosine (Y173) that relieves CH-domain autoinhibition, and VAV3 is recruited to activated receptor tyrosine kinases (EGFR, Ros, IR, IGF-IR, EphA2, ERBB4) and immune-receptor complexes (via SH2-domain binding to phospho-SLP-76 and phospho-3BP2) to drive actin cytoskeletal reorganization, cell migration, cytokinesis, and specialized functions in osteoclasts (downstream of Syk and αvβ3 integrin), endothelial barrier integrity (via Rap1), and B-cell signaling (sustaining PIP3/PI3K–Rac1 positive feedback); in the nucleus, VAV3 acts as a GEF-activity-dependent co-activator of PRC1 (interacting with Bmi1, Ring1b, Ezh2) and, in a GEF-independent but PH-domain-dependent manner, as a co-activator of androgen receptor (AR) and estrogen receptor (ERα) by promoting AR N-C interaction and chromatin recruitment; VAV3 expression is transcriptionally controlled by the aryl hydrocarbon receptor (AhR) and BCL11A, and post-transcriptionally stabilized by HuR binding to its mRNA and by DDX5/METTL3-mediated m6A modification recognized by IGF2BP1."},"narrative":{"mechanistic_narrative":"VAV3 is a tyrosine phosphorylation-regulated guanine nucleotide exchange factor (GEF) that activates the Rho-family GTPases RhoA, RhoG, Rac1, and Cdc42 to drive actin cytoskeletal reorganization, cell migration, and cytokinesis [PMID:10523675, PMID:11094073]. Catalysis requires the DH domain working coordinately with the adjacent ZF region, and basal activity is held in check by the N-terminal calponin-homology (CH) domain whose deletion renders VAV3 constitutively active [PMID:10523675]; tyrosine phosphorylation drives global conformational rearrangements that distinguish inactive, phosphorylated, and oncogenically truncated states [PMID:15775967]. VAV3 is recruited to and phosphorylated downstream of multiple receptor tyrosine kinases—EGFR, Ros, the insulin receptor, IGF-IR, EphA2, and ERBB4—and of oncogenic fusion kinases such as NPM-ALK, binding their phosphotyrosines through its SH2 domain to couple receptor activation to Rac1-driven motility and invasion [PMID:11094073, PMID:17998938, PMID:22659453, PMID:32561640]. In immune-receptor signaling, the SH2 domain links VAV3 to phospho-SLP-76 at the immunological synapse and to Syk-phosphorylated 3BP2, positioning it downstream of antigen and ITAM receptors to support Rac1 activation, NFAT signaling, and a Rac1–PI3K positive feedback loop that sustains PIP3 generation in B cells [PMID:11805146, PMID:15708849, PMID:24406398]. VAV3 executes specialized GTPase-dependent programs in distinct tissues: it is essential for osteoclast actin organization and bone resorption downstream of Syk, the M-CSF receptor, αvβ3 integrin, and TRAF6/RANK [PMID:15711558, PMID:27507811, PMID:40787875]; it maintains endothelial barrier integrity via DH-domain-dependent Rap1 activation [PMID:29858212]; and it regulates vascular smooth muscle proliferation through Rac1/PAK [PMID:19969623] and oligodendrocyte myelination through RhoA [PMID:30450647]. Beyond cytoplasmic GTPase signaling, VAV3 acts in the nucleus: in a GEF-independent, PH-domain-dependent manner it co-activates androgen and estrogen receptors by promoting AR N–C interaction and chromatin co-recruitment [PMID:16384856, PMID:21765461, PMID:18518979], while in BCR-ABL leukemia its nuclear GEF activity drives PRC1-dependent H2AK119 mono-ubiquitination and Bmi1-dependent progenitor self-renewal [PMID:35650206, PMID:22692505]. VAV3 expression is controlled transcriptionally by the aryl hydrocarbon receptor and BCL11A [PMID:19158396, PMID:21115475, PMID:40855003] and post-transcriptionally stabilized by HuR and by m6A modification, contributing to disease phenotypes including cystic fibrosis airway pathology and cancer [PMID:36602863, PMID:39289531, PMID:32640241]. Loss of VAV3 in mice causes sympathetic hyperactivity, hypertension, and cardiovascular remodeling [PMID:16767097].","teleology":[{"year":1999,"claim":"Established VAV3's core biochemical identity by showing it is a Rho-family GEF whose catalytic DH domain works with the ZF region and is held autoinhibited by the CH domain.","evidence":"in vitro nucleotide exchange assays, GTPase binding, and CH-deletion mutagenesis with actin cytoskeleton readouts in transfected cells","pmids":["10523675"],"confidence":"High","gaps":["GTPase preference (RhoA/RhoG vs Rac1/Cdc42) varied with construct","physiological trigger of phosphorylation not defined in this study"]},{"year":2000,"claim":"Connected VAV3 to receptor tyrosine kinase signaling, showing it is phosphorylated downstream of EGFR/Ros/IR/IGF-IR and links to Shc, Grb2, PLC-γ, and PI3K.","evidence":"yeast two-hybrid, co-IP, GST-fusion GTPase activation assays, domain mutagenesis in 293T/NIH 3T3 cells","pmids":["11094073"],"confidence":"High","gaps":["direct vs adaptor-mediated receptor binding not fully resolved","cell-type specificity of GTPase output unaddressed"]},{"year":2002,"claim":"Defined VAV3 regulation of cytokinesis and transformation, identifying the Y173 regulatory tyrosine and the PI3K/Akt–Rac1/RhoA/Cdc42 requirements for transforming and motility activity.","evidence":"cell-cycle synchronization, focus-formation and motility assays, phospho-site and dominant-negative GTPase mutants","pmids":["11917103","11884391"],"confidence":"High","gaps":["mechanism coupling cytokinesis to RhoA not detailed","physiological role of mitotic upregulation unknown"]},{"year":2002,"claim":"Showed VAV3 sustains PIP3/PI3K–Rac1 feedback in B-cell receptor signaling, positioning it as an amplifier of lipid second messengers.","evidence":"B-cell knockout, dominant-negative Rac1, PIP3/PI3K assays, SHIP-deletion rescue","pmids":["11805146"],"confidence":"High","gaps":["direct PI3K activation mechanism by Rac1 not structurally defined"]},{"year":2004,"claim":"Established functional redundancy of VAV3 with VAV1 in ITAM/GPVI signaling, explaining mild single-knockout phenotypes.","evidence":"single and double knockout mice, platelet aggregation/spreading and PLCγ2 phosphorylation assays","pmids":["15456756"],"confidence":"High","gaps":["non-redundant VAV3-specific roles in platelets not identified"]},{"year":2005,"claim":"Resolved the conformational basis of VAV3 activation, showing phosphorylation drives global rearrangements distinct from N-terminal truncation.","evidence":"single-particle electron microscopy of three functional states","pmids":["15775967"],"confidence":"High","gaps":["atomic-resolution structure absent","dynamics of intermediate states not captured"]},{"year":2005,"claim":"Placed VAV3 in immune-receptor and osteoclast pathways, linking SH2-mediated SLP-76 binding to synapse recruitment and Syk/integrin signaling to bone resorption.","evidence":"SH2-domain mutants, signaling-deficient cell lines, NFAT reporter, Vav3-knockout osteoclast assays, bone density measurement","pmids":["15708849","15711558"],"confidence":"High","gaps":["how distinct receptors select VAV3 GTPase output not resolved"]},{"year":2005,"claim":"Showed VAV3 couples local PIP3 to Rac1/Cdc42 feedback for directed protrusion during neurite outgrowth, generalizing the lipid-feedback mechanism.","evidence":"FRET biosensors and RNAi in PC12 cells","pmids":["15728722"],"confidence":"High","gaps":["VAV2 vs VAV3 specific contributions not separated"]},{"year":2005,"claim":"Revealed a non-canonical, GEF-independent nuclear receptor co-activator role: VAV3 potentiates AR via its PH domain without direct binding or AF1-independent mechanisms.","evidence":"AR reporter assays, PH/domain deletions, co-IP (negative for direct AR binding)","pmids":["16384856"],"confidence":"Medium","gaps":["intermediary linking VAV3 to AR not identified here","single lab"]},{"year":2006,"claim":"Linked VAV3 to androgen-independent prostate cancer and to AR activation through the DH domain and PI3K-Akt pathway, partially reconciling GEF and co-activator roles.","evidence":"knockdown/overexpression, AR reporter, PI3K inhibition, dominant-negative Akt","pmids":["16762975"],"confidence":"Medium","gaps":["reconciliation of DH-dependent vs GEF-independent AR activation incomplete","single lab"]},{"year":2006,"claim":"Demonstrated a physiological in vivo role: VAV3 loss causes sympathetic hyperactivity, hypertension, and cardiovascular remodeling.","evidence":"knockout mice, blood pressure/catecholamine measurement, pharmacological pathway dissection","pmids":["16767097"],"confidence":"High","gaps":["cell-autonomous neuronal mechanism of VAV3 in sympathetic neurons not defined"]},{"year":2009,"claim":"Identified AhR as a ligand-independent transcriptional regulator of VAV3 controlling Rac1/RhoA balance and cell morphology.","evidence":"ChIP at vav3 promoter, AhR-/- and Vav3-/- MEFs, rescue, GTPase activity and morphology assays","pmids":["19158396"],"confidence":"High","gaps":["AhR target-gene context beyond vav3 not mapped"]},{"year":2009,"claim":"Extended GEF function to vascular smooth muscle proliferation/migration via Rac1/PAK, confirming catalytic dependence in vivo.","evidence":"RhoGEF siRNA screen, catalytic mutant, dominant-negative Rac1, PAK assay, stented artery model","pmids":["19969623"],"confidence":"High","gaps":["upstream receptor driving VSMC VAV3 activation not specified"]},{"year":2010,"claim":"Confirmed the AhR–VAV3 axis in vivo across tissues, showing overlapping cardiorespiratory and autonomic phenotypes.","evidence":"parallel Ahr-/- and Vav3-/- mouse phenotyping across multiple organs","pmids":["21115475"],"confidence":"High","gaps":["molecular link from VAV3 to GABAergic transmission unresolved"]},{"year":2011,"claim":"Resolved the nuclear AR co-activation mechanism: PH-dependent nuclear localization enables VAV3/AR co-recruitment to enhancers and stimulation of AR N–C interaction.","evidence":"fractionation, nuclear/membrane targeting constructs, sequential ChIP, N-C interaction and reporter assays","pmids":["21765461"],"confidence":"High","gaps":["chromatin-associated VAV3 binding partners incompletely defined"]},{"year":2012,"claim":"Connected VAV3 to RTK and fusion-kinase-driven cancer (EphA2, NPM-ALK) and to AR splice-variant-driven CRPC, broadening its oncogenic SH2-coupled signaling.","evidence":"co-IP, SH2 domain mapping, Rac1 assays, shRNA, AR-V7/ARv567es reporter assays, in vivo metastasis models","pmids":["22659453","17998938","23023561"],"confidence":"High","gaps":["relative weighting of GEF vs scaffolding contributions in tumors varies by study"]},{"year":2012,"claim":"Defined VAV3's role in BCR-ABL leukemogenesis with Rac2 as a downstream effector and identified Cdc37 as a co-activator partner for AR signaling.","evidence":"multiple Vav-knockout leukemia models, apoptosis/GTPase assays, TKI combinations; yeast two-hybrid and Co-IP for Cdc37","pmids":["22692505","23281476"],"confidence":"High","gaps":["Cdc37 mechanism on VAV3 conformation unknown (no effect on GEF activity/localization)"]},{"year":2014,"claim":"Positioned VAV3 downstream of ERα in endocrine-resistant breast cancer survival and mapped the 3BP2–VAV3 SH2 link in BCR signaling.","evidence":"shRNA depletion with ERα epistasis; 3BP2 phospho-site mutagenesis and Rac1 assays in DT40 B cells","pmids":["24886537","24406398"],"confidence":"Medium","gaps":["direct vs indirect ERα–VAV3 regulation not resolved","single-lab studies"]},{"year":2016,"claim":"Identified a ubiquitination-independent TRAF6–VAV3 interaction within the RANK signaling complex driving osteoclastogenesis.","evidence":"proteomic screen, co-IP, domain mapping, RANK tail mutants, NF-κB/MAPK/NFATc1 assays","pmids":["27507811"],"confidence":"High","gaps":["structural basis of TRAF6 coiled-coil/VAV3 DH contact undefined"]},{"year":2017,"claim":"Characterized atypical regulatory features—the non-DAG-binding C1 domain and DNMT3B-mediated promoter methylation—affecting VAV3 activity and expression.","evidence":"C1 domain mutagenesis with GEF/localization assays; DNMT3B overexpression with methylation analysis","pmids":["28927664","28123849"],"confidence":"Medium","gaps":["physiological relevance of C1 atypicality unclear","DNMT3B regulation shown by single method"]},{"year":2018,"claim":"Defined a DH-dependent Rap1 mechanism for VAV3 in endothelial barrier integrity and a RhoA-dependent role in oligodendrocyte myelination.","evidence":"endothelial DH mutant and Rap1 epistasis with in vivo permeability; Vav3-knockout myelination models with FRET RhoA biosensors","pmids":["29858212","30450647"],"confidence":"High","gaps":["how VAV3 selects Rap1 vs Rho-family output in different cells unknown"]},{"year":2020,"claim":"Established ERBB4 as a VAV3-activating RTK in breast cancer migration and revealed VAV3's contribution to cystic fibrosis airway pathology via β1-integrin/fibronectin platforms for bacterial adhesion.","evidence":"MS interactome, ERBB4 kinase/phospho-site and VAV3 SH2 mutants, migration assays; RNA-seq, knockdown, co-localization, bacterial adhesion assays","pmids":["32561640","32640241"],"confidence":"High","gaps":["GEF-dependence of CF integrin platform formation not fully dissected"]},{"year":2021,"claim":"Validated VAV3 as a druggable target by identifying IODVA1, a direct binder that inhibits RAC activation and BCR-ABL1 leukemia in a VAV3-dependent manner.","evidence":"small-molecule binding, Vav3-null genetic control, RAC assays, leukemia models and PDX","pmids":["34711926"],"confidence":"High","gaps":["binding site on VAV3 not structurally defined"]},{"year":2022,"claim":"Uncovered a non-canonical nuclear GEF mechanism: VAV3 interacts with PRC1 (Bmi1, Ring1b, Ezh2) and drives H2AK119 mono-ubiquitination and Bmi1-dependent leukemic progenitor self-renewal.","evidence":"nuclear fractionation/Co-IP, GEF-dead mutants, H2AK119Ub ChIP, Akt/Phlpp2/Bmi1 phospho-analysis in Vav3-null leukemia","pmids":["35650206"],"confidence":"High","gaps":["how nuclear Rac activity feeds PRC1 mechanistically not fully resolved"]},{"year":2023,"claim":"Established post-transcriptional control of VAV3 by HuR mRNA stabilization driving CF airway overexpression.","evidence":"RIP for HuR-Vav3 mRNA, interaction disruption, epithelial integrity and bacterial adhesion assays","pmids":["36602863"],"confidence":"Medium","gaps":["signal triggering cytoplasmic HuR accumulation in CF not defined","single lab"]},{"year":2024,"claim":"Expanded VAV3 regulation to m6A modification (DDX5/METTL3/IGF2BP1) in carcinoma and revealed a STAT3-repressed metabolic role in hepatic glucose/cholesterol homeostasis.","evidence":"RIP, m6A modification and stability assays; HFD model, GLUT4 trafficking and glucose assays, rAAV8 rescue","pmids":["39289531","38617550"],"confidence":"Medium","gaps":["mechanism of VAV3 in GLUT4 trafficking and cholesterol metabolism not biochemically defined","single labs"]},{"year":2025,"claim":"Identified BCL11A as a transcriptional regulator of VAV3 in cerebellar Purkinje cells and refined the SYK–VAV3 osteoclast leading-edge mechanism.","evidence":"conditional Bcl11a knockout with Vav3 rescue and behavioral/electrophysiology readouts; SYK knockdown with co-localization, actin ring and bone resorption assays","pmids":["40855003","40787875"],"confidence":"High","gaps":["direct vs indirect BCL11A regulation of vav3 promoter not shown","SYK study single lab"]},{"year":null,"claim":"How VAV3's distinct functional modes—cytoplasmic GTPase exchange, nuclear PRC1 co-activation, and GEF-independent nuclear receptor co-activation—are selected and integrated within a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["no unified model linking conformational state to nuclear vs cytoplasmic output","atomic structures of active complexes lacking","rules governing GTPase substrate selection across tissues undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[12,16,19,35]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,10,32]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,19]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[19,35]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,27,33]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[1,8,40]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,6,10,32]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,7,10,30]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[12,19,35]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[14,21,33,35]}],"complexes":["PRC1 (Bmi1/Ring1b/Ezh2)","RANK-TRAF6 signaling complex","NPM-ALK/Src/Lyn complex"],"partners":["SLP76","TRAF6","ERBB4","EPHA2","SH3BP2","CDC37","BMI1","STAP2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UKW4","full_name":"Guanine nucleotide exchange factor VAV3","aliases":[],"length_aa":847,"mass_kda":97.8,"function":"Exchange factor for GTP-binding proteins RhoA, RhoG and, to a lesser extent, Rac1. Binds physically to the nucleotide-free states of those GTPases. Plays an important role in angiogenesis. Its recruitment by phosphorylated EPHA2 is critical for EFNA1-induced RAC1 GTPase activation and vascular endothelial cell migration and assembly (By similarity). May be important for integrin-mediated signaling, at least in some cell types. In osteoclasts, along with SYK tyrosine kinase, required for signaling through integrin alpha-v/beta-1 (ITAGV-ITGB1), a crucial event for osteoclast proper cytoskeleton organization and function. This signaling pathway involves RAC1, but not RHO, activation. Necessary for proper wound healing. In the course of wound healing, required for the phagocytotic cup formation preceding macrophage phagocytosis of apoptotic neutrophils. Responsible for integrin beta-2 (ITGB2)-mediated macrophage adhesion and, to a lesser extent, contributes to beta-3 (ITGB3)-mediated adhesion. Does not affect integrin beta-1 (ITGB1)-mediated adhesion (By similarity)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q9UKW4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/VAV3","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/VAV3","total_profiled":1310},"omim":[{"mim_id":"616347","title":"PR DOMAIN-CONTAINING PROTEIN 11; PRDM11","url":"https://www.omim.org/entry/616347"},{"mim_id":"605541","title":"VAV GUANINE NUCLEOTIDE EXCHANGE FACTOR 3; VAV3","url":"https://www.omim.org/entry/605541"},{"mim_id":"604213","title":"CHUDLEY-MCCULLOUGH SYNDROME; CMCS","url":"https://www.omim.org/entry/604213"},{"mim_id":"600428","title":"VAV GUANINE NUCLEOTIDE EXCHANGE FACTOR 2; VAV2","url":"https://www.omim.org/entry/600428"},{"mim_id":"600085","title":"PROTEIN-TYROSINE KINASE SYK; SYK","url":"https://www.omim.org/entry/600085"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"kidney","ntpm":78.4}],"url":"https://www.proteinatlas.org/search/VAV3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9UKW4","domains":[{"cath_id":"1.10.418.10","chopping":"4-149","consensus_level":"high","plddt":89.8309,"start":4,"end":149},{"cath_id":"1.20.900.10","chopping":"191-376","consensus_level":"high","plddt":94.1416,"start":191,"end":376},{"cath_id":"2.30.29.30","chopping":"391-505","consensus_level":"medium","plddt":89.2915,"start":391,"end":505},{"cath_id":"3.30.60.20","chopping":"512-559","consensus_level":"medium","plddt":93.4106,"start":512,"end":559},{"cath_id":"2.30.30.40","chopping":"597-658","consensus_level":"medium","plddt":84.2532,"start":597,"end":658},{"cath_id":"3.30.505.10","chopping":"674-766","consensus_level":"high","plddt":86.9075,"start":674,"end":766},{"cath_id":"2.30.30.40","chopping":"792-846","consensus_level":"high","plddt":80.5938,"start":792,"end":846}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UKW4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UKW4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UKW4-F1-predicted_aligned_error_v6.png","plddt_mean":84.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=VAV3","jax_strain_url":"https://www.jax.org/strain/search?query=VAV3"},"sequence":{"accession":"Q9UKW4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UKW4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UKW4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UKW4"}},"corpus_meta":[{"pmid":"10523675","id":"PMC_10523675","title":"Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10523675","citation_count":237,"is_preprint":false},{"pmid":"15711558","id":"PMC_15711558","title":"Vav3 regulates osteoclast function and bone mass.","date":"2005","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15711558","citation_count":226,"is_preprint":false},{"pmid":"19008376","id":"PMC_19008376","title":"The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma.","date":"2008","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19008376","citation_count":152,"is_preprint":false},{"pmid":"11094073","id":"PMC_11094073","title":"Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11094073","citation_count":127,"is_preprint":false},{"pmid":"15728722","id":"PMC_15728722","title":"Local phosphatidylinositol 3,4,5-trisphosphate accumulation recruits Vav2 and Vav3 to activate Rac1/Cdc42 and initiate neurite outgrowth in nerve growth factor-stimulated PC12 cells.","date":"2005","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15728722","citation_count":124,"is_preprint":false},{"pmid":"11805146","id":"PMC_11805146","title":"Vav3 modulates B cell receptor responses by regulating phosphoinositide 3-kinase activation.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11805146","citation_count":115,"is_preprint":false},{"pmid":"23033540","id":"PMC_23033540","title":"The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells.","date":"2012","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/23033540","citation_count":96,"is_preprint":false},{"pmid":"31959200","id":"PMC_31959200","title":"Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression.","date":"2020","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31959200","citation_count":93,"is_preprint":false},{"pmid":"16767097","id":"PMC_16767097","title":"Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction.","date":"2006","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16767097","citation_count":91,"is_preprint":false},{"pmid":"27930970","id":"PMC_27930970","title":"Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling.","date":"2016","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27930970","citation_count":85,"is_preprint":false},{"pmid":"15456756","id":"PMC_15456756","title":"Vav1 and vav3 have critical but redundant roles in mediating platelet activation by collagen.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15456756","citation_count":80,"is_preprint":false},{"pmid":"11884391","id":"PMC_11884391","title":"Distinct role of phosphatidylinositol 3-kinase and Rho family GTPases in Vav3-induced cell transformation, cell motility, and morphological changes.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11884391","citation_count":70,"is_preprint":false},{"pmid":"16762975","id":"PMC_16762975","title":"Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.","date":"2006","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/16762975","citation_count":67,"is_preprint":false},{"pmid":"19158396","id":"PMC_19158396","title":"The dioxin receptor regulates the constitutive expression of the vav3 proto-oncogene and modulates cell shape and adhesion.","date":"2009","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/19158396","citation_count":67,"is_preprint":false},{"pmid":"33408524","id":"PMC_33408524","title":"Exosomal miR-499a-5p Inhibits Endometrial Cancer Growth and Metastasis via Targeting VAV3.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/33408524","citation_count":62,"is_preprint":false},{"pmid":"18518979","id":"PMC_18518979","title":"Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer.","date":"2008","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18518979","citation_count":60,"is_preprint":false},{"pmid":"22659453","id":"PMC_22659453","title":"Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22659453","citation_count":59,"is_preprint":false},{"pmid":"16384856","id":"PMC_16384856","title":"Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.","date":"2005","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/16384856","citation_count":58,"is_preprint":false},{"pmid":"21115475","id":"PMC_21115475","title":"Transcriptional factor aryl hydrocarbon receptor (Ahr) controls cardiovascular and respiratory functions by regulating the expression of the Vav3 proto-oncogene.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21115475","citation_count":55,"is_preprint":false},{"pmid":"20140222","id":"PMC_20140222","title":"VAV2 and VAV3 as candidate disease genes for spontaneous glaucoma in mice and humans.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20140222","citation_count":49,"is_preprint":false},{"pmid":"17998938","id":"PMC_17998938","title":"Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17998938","citation_count":49,"is_preprint":false},{"pmid":"23023561","id":"PMC_23023561","title":"Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.","date":"2012","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23023561","citation_count":48,"is_preprint":false},{"pmid":"26972445","id":"PMC_26972445","title":"Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26972445","citation_count":44,"is_preprint":false},{"pmid":"21765461","id":"PMC_21765461","title":"A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21765461","citation_count":44,"is_preprint":false},{"pmid":"30608205","id":"PMC_30608205","title":"Circular RNA Vav3 sponges gga-miR-375 to promote epithelial-mesenchymal transition.","date":"2019","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/30608205","citation_count":40,"is_preprint":false},{"pmid":"22692505","id":"PMC_22692505","title":"Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22692505","citation_count":39,"is_preprint":false},{"pmid":"20089829","id":"PMC_20089829","title":"Vav3-deficient mice exhibit a transient delay in cerebellar development.","date":"2010","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/20089829","citation_count":39,"is_preprint":false},{"pmid":"15775967","id":"PMC_15775967","title":"Global conformational rearrangements during the activation of the GDP/GTP exchange factor Vav3.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15775967","citation_count":37,"is_preprint":false},{"pmid":"11917103","id":"PMC_11917103","title":"Vav3 is regulated during the cell cycle and effects cell division.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11917103","citation_count":36,"is_preprint":false},{"pmid":"10713454","id":"PMC_10713454","title":"Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors.","date":"2000","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/10713454","citation_count":36,"is_preprint":false},{"pmid":"20126983","id":"PMC_20126983","title":"The molecular mechanism of Vav3 oncogene on upregulation of androgen receptor activity in prostate cancer cells.","date":"2010","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20126983","citation_count":36,"is_preprint":false},{"pmid":"15708849","id":"PMC_15708849","title":"Membrane localization and function of Vav3 in T cells depend on its association with the adapter SLP-76.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15708849","citation_count":35,"is_preprint":false},{"pmid":"18676865","id":"PMC_18676865","title":"Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18676865","citation_count":35,"is_preprint":false},{"pmid":"20463313","id":"PMC_20463313","title":"Variations in NTF4, VAV2, and VAV3 genes are not involved with primary open-angle and primary angle-closure glaucomas in an indian population.","date":"2010","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/20463313","citation_count":34,"is_preprint":false},{"pmid":"24886537","id":"PMC_24886537","title":"VAV3 mediates resistance to breast cancer endocrine therapy.","date":"2014","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/24886537","citation_count":31,"is_preprint":false},{"pmid":"19969623","id":"PMC_19969623","title":"The Rho protein exchange factor Vav3 regulates vascular smooth muscle cell proliferation and migration.","date":"2009","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/19969623","citation_count":30,"is_preprint":false},{"pmid":"29858212","id":"PMC_29858212","title":"Vav3-induced cytoskeletal dynamics contribute to heterotypic properties of endothelial barriers.","date":"2018","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29858212","citation_count":30,"is_preprint":false},{"pmid":"20363978","id":"PMC_20363978","title":"Nonobese diabetic congenic strain analysis of autoimmune diabetes reveals genetic complexity of the Idd18 locus and identifies Vav3 as a candidate gene.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20363978","citation_count":29,"is_preprint":false},{"pmid":"33109774","id":"PMC_33109774","title":"LINC00265 targets miR-382-5p to regulate SAT1, VAV3 and angiogenesis in osteosarcoma.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33109774","citation_count":25,"is_preprint":false},{"pmid":"30450647","id":"PMC_30450647","title":"The guanine nucleotide exchange factor Vav3 modulates oligodendrocyte precursor differentiation and supports remyelination in white matter lesions.","date":"2018","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/30450647","citation_count":25,"is_preprint":false},{"pmid":"24072493","id":"PMC_24072493","title":"Inhibition of gastric cancer cell growth and invasion through siRNA-mediated knockdown of guanine nucleotide exchange factor Vav3.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24072493","citation_count":24,"is_preprint":false},{"pmid":"28123849","id":"PMC_28123849","title":"DNMT3B modulates the expression of cancer-related genes and downregulates the expression of the gene VAV3 via methylation.","date":"2017","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28123849","citation_count":24,"is_preprint":false},{"pmid":"20190565","id":"PMC_20190565","title":"A remarkable new target gene for the dioxin receptor: The Vav3 proto-oncogene links AhR to adhesion and migration.","date":"2010","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/20190565","citation_count":23,"is_preprint":false},{"pmid":"22544459","id":"PMC_22544459","title":"Clinical significance of increased guanine nucleotide exchange factor Vav3 expression in human gastric cancer.","date":"2012","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/22544459","citation_count":23,"is_preprint":false},{"pmid":"23566222","id":"PMC_23566222","title":"Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.","date":"2013","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23566222","citation_count":23,"is_preprint":false},{"pmid":"32640241","id":"PMC_32640241","title":"Vav3 Mediates Pseudomonas aeruginosa Adhesion to the Cystic Fibrosis Airway Epithelium.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32640241","citation_count":22,"is_preprint":false},{"pmid":"28214347","id":"PMC_28214347","title":"Involvement of the guanine nucleotide exchange factor Vav3 in central nervous system development and plasticity.","date":"2017","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28214347","citation_count":22,"is_preprint":false},{"pmid":"12400014","id":"PMC_12400014","title":"Adaptor protein APS binds the NH2-terminal autoinhibitory domain of guanine nucleotide exchange factor Vav3 and augments its activity.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12400014","citation_count":22,"is_preprint":false},{"pmid":"27143812","id":"PMC_27143812","title":"Detection of OSR2, VAV3, and PPFIA3 Methylation in the Serum of Patients with Gastric Cancer.","date":"2016","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/27143812","citation_count":21,"is_preprint":false},{"pmid":"23281476","id":"PMC_23281476","title":"Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23281476","citation_count":19,"is_preprint":false},{"pmid":"33869908","id":"PMC_33869908","title":"miR-155-5p predictive role to decelerate foam cell atherosclerosis through CD36, VAV3, and SOCS1 pathway.","date":"2021","source":"Non-coding RNA research","url":"https://pubmed.ncbi.nlm.nih.gov/33869908","citation_count":16,"is_preprint":false},{"pmid":"25501893","id":"PMC_25501893","title":"The guanine nucleotide exchange factor Vav3 regulates differentiation of progenitor cells in the developing mouse retina.","date":"2014","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/25501893","citation_count":16,"is_preprint":false},{"pmid":"22416266","id":"PMC_22416266","title":"Analysis of the VAV3 as candidate gene for schizophrenia: evidences from voxel-based morphometry and mutation screening.","date":"2012","source":"Schizophrenia bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/22416266","citation_count":16,"is_preprint":false},{"pmid":"27507811","id":"PMC_27507811","title":"Interaction of Tumor Necrosis Factor Receptor-associated Factor 6 (TRAF6) and Vav3 in the Receptor Activator of Nuclear Factor κB (RANK) Signaling Complex Enhances Osteoclastogenesis.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27507811","citation_count":15,"is_preprint":false},{"pmid":"25430880","id":"PMC_25430880","title":"Inhibition of Vav3 could reverse the drug resistance of gastric cancer cells by downregulating JNK signaling pathway.","date":"2014","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25430880","citation_count":15,"is_preprint":false},{"pmid":"38617550","id":"PMC_38617550","title":"The role of STAT3/VAV3 in glucolipid metabolism during the development of HFD-induced MAFLD.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38617550","citation_count":14,"is_preprint":false},{"pmid":"32561640","id":"PMC_32561640","title":"The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32561640","citation_count":14,"is_preprint":false},{"pmid":"21455584","id":"PMC_21455584","title":"Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.","date":"2011","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21455584","citation_count":14,"is_preprint":false},{"pmid":"37783052","id":"PMC_37783052","title":"Serum exosome-derived miR-146a-3p promotes macrophage M2 polarization in allergic rhinitis by targeting VAV3 via PI3K/AKT/mTOR pathway.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37783052","citation_count":14,"is_preprint":false},{"pmid":"23403204","id":"PMC_23403204","title":"The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia.","date":"2013","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23403204","citation_count":12,"is_preprint":false},{"pmid":"33221374","id":"PMC_33221374","title":"HDAC1 promotes artery injury through activation of VAV3 by binding to miR-182-5p in atherosclerotic mice model.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/33221374","citation_count":12,"is_preprint":false},{"pmid":"35650206","id":"PMC_35650206","title":"Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35650206","citation_count":11,"is_preprint":false},{"pmid":"34711926","id":"PMC_34711926","title":"Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.","date":"2021","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/34711926","citation_count":11,"is_preprint":false},{"pmid":"36602863","id":"PMC_36602863","title":"Targeting HuR-Vav3 mRNA interaction prevents Pseudomonas aeruginosa adhesion to the cystic fibrosis airway epithelium.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36602863","citation_count":10,"is_preprint":false},{"pmid":"26695150","id":"PMC_26695150","title":"Inhibition of Vav3 gene can promote apoptosis of human gastric cancer cell line MGC803 by regulating ERK pathway.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26695150","citation_count":10,"is_preprint":false},{"pmid":"24406398","id":"PMC_24406398","title":"Tyrosine phosphorylation of 3BP2 is indispensable for the interaction with VAV3 in chicken DT40 cells.","date":"2014","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/24406398","citation_count":10,"is_preprint":false},{"pmid":"39289531","id":"PMC_39289531","title":"DDX5 promotes esophageal squamous cell carcinoma growth through sustaining VAV3 mRNA stability.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39289531","citation_count":9,"is_preprint":false},{"pmid":"37467637","id":"PMC_37467637","title":"VAV3 in human cancers: Mechanism and clinical implication.","date":"2023","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/37467637","citation_count":9,"is_preprint":false},{"pmid":"36960857","id":"PMC_36960857","title":"VAV3 regulates glioblastoma cell proliferation, migration, invasion and cancer stem‑like cell self‑renewal.","date":"2023","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/36960857","citation_count":9,"is_preprint":false},{"pmid":"25309796","id":"PMC_25309796","title":"Vav3, a GEF for RhoA, Plays a Critical Role under High Glucose Conditions.","date":"2014","source":"Endocrinology and metabolism (Seoul, Korea)","url":"https://pubmed.ncbi.nlm.nih.gov/25309796","citation_count":9,"is_preprint":false},{"pmid":"32013053","id":"PMC_32013053","title":"Deletion of the Nucleotide Exchange Factor Vav3 Enhances Axonal Complexity and Synapse Formation but Tampers Activity of Hippocampal Neuronal Networks In Vitro.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32013053","citation_count":8,"is_preprint":false},{"pmid":"23402756","id":"PMC_23402756","title":"Molecular genetic analysis of primary open-angle glaucoma, normal tension glaucoma, and developmental glaucoma for the VAV2 and VAV3 gene variants in Japanese subjects.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23402756","citation_count":7,"is_preprint":false},{"pmid":"32540412","id":"PMC_32540412","title":"VAV3 rs7528153 and VAV3-AS1 rs1185222 polymorphisms are associated with an increased risk of developing hypertension.","date":"2020","source":"European journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32540412","citation_count":6,"is_preprint":false},{"pmid":"37591108","id":"PMC_37591108","title":"The role of Vav3 expression for inflammation and cell death during experimental myocardial infarction.","date":"2023","source":"Clinics (Sao Paulo, Brazil)","url":"https://pubmed.ncbi.nlm.nih.gov/37591108","citation_count":5,"is_preprint":false},{"pmid":"35534539","id":"PMC_35534539","title":"The Rho guanosine nucleotide exchange factors Vav2 and Vav3 modulate epidermal stem cell function.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35534539","citation_count":5,"is_preprint":false},{"pmid":"28937614","id":"PMC_28937614","title":"A Novel Vav3 Homolog Identified in Lamprey, Lampetra japonica, with Roles in Lipopolysaccharide-Mediated Immune Response.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28937614","citation_count":5,"is_preprint":false},{"pmid":"36531963","id":"PMC_36531963","title":"The guanine nucleotide exchange factor Vav3 intervenes in the migration pathway of oligodendrocyte precursor cells on tenascin-C.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36531963","citation_count":5,"is_preprint":false},{"pmid":"27172236","id":"PMC_27172236","title":"VAV3 Gene Polymorphism Is Associated with Paget's Disease of Bone.","date":"2016","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/27172236","citation_count":4,"is_preprint":false},{"pmid":"35237130","id":"PMC_35237130","title":"Vav3-Deficient Astrocytes Enhance the Dendritic Development of Hippocampal Neurons in an Indirect Co-culture System.","date":"2022","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35237130","citation_count":4,"is_preprint":false},{"pmid":"29674438","id":"PMC_29674438","title":"(Iso-)form Matters: Differential Implication of Vav3 Variants in Ovarian Cancer.","date":"2018","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/29674438","citation_count":4,"is_preprint":false},{"pmid":"28513273","id":"PMC_28513273","title":"The clinical value of Vav3 in peripheral blood for predicting lymphatic metastasis of gastric cancer.","date":"2017","source":"British journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/28513273","citation_count":4,"is_preprint":false},{"pmid":"40618919","id":"PMC_40618919","title":"Unravelling the roles of Vav3 in cytoskeletal control and angiogenesis.","date":"2025","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40618919","citation_count":3,"is_preprint":false},{"pmid":"39987600","id":"PMC_39987600","title":"Circular RNA Vav3 mediated ALV-J inhibition of autophagy by modulating the gga-miR-375/CIP2A axis and activating AKT.","date":"2025","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/39987600","citation_count":3,"is_preprint":false},{"pmid":"28927664","id":"PMC_28927664","title":"The C1 domain of Vav3, a novel potential therapeutic target.","date":"2017","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/28927664","citation_count":3,"is_preprint":false},{"pmid":"27430689","id":"PMC_27430689","title":"[Association between polymorphism in Vav3 genes and risk of primary prostatic cancer in Chinese Han population].","date":"2016","source":"Zhonghua bing li xue za zhi = Chinese journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27430689","citation_count":3,"is_preprint":false},{"pmid":"34292486","id":"PMC_34292486","title":"The effect of VAV3 polymorphisms on thyroid cancer.","date":"2021","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/34292486","citation_count":2,"is_preprint":false},{"pmid":"37092056","id":"PMC_37092056","title":"Rs7537605 polymorphism in VAV3 gene and rs28665122 polymorphism in SEPS gene are not associated with Hashimoto's thyroiditis in North-East Algerian population.","date":"2022","source":"African health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37092056","citation_count":1,"is_preprint":false},{"pmid":"40787875","id":"PMC_40787875","title":"Spleen Tyrosine Kinase Exacerbates Anti-Citrullinated Protein/Peptide Antibody-Mediated Osteoclast Bone Resorption via Promotion of Vav3 Phosphorylation.","date":"2025","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/40787875","citation_count":1,"is_preprint":false},{"pmid":"25975784","id":"PMC_25975784","title":"[Effect and mechanism of Vav3 on the proliferation of human gastric cancer SGC7901 cells].","date":"2015","source":"Zhonghua zhong liu za zhi [Chinese journal of oncology]","url":"https://pubmed.ncbi.nlm.nih.gov/25975784","citation_count":1,"is_preprint":false},{"pmid":"42248330","id":"PMC_42248330","title":"VAV3 is associated with atherosclerosis and ox-LDL-induced endothelial dysfunctional remodeling.","date":"2026","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/42248330","citation_count":0,"is_preprint":false},{"pmid":"40855003","id":"PMC_40855003","title":"Bcl11a deficiency in cerebellar Purkinje cells causes ataxia and autistic-like behavior by altering Vav3.","date":"2025","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/40855003","citation_count":0,"is_preprint":false},{"pmid":"42083314","id":"PMC_42083314","title":"Indirubin Sensitizes Prostate Cancer to Docetaxel by Inhibiting Autophagy Through the circ-Vav3/miR-204-5p/MAPK1 Pathway.","date":"2026","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/42083314","citation_count":0,"is_preprint":false},{"pmid":"42056214","id":"PMC_42056214","title":"Resibufogenin promotes angiogenesis via the VAV3-mediated ITGA5-VEGF signaling axis in macrophages to alleviate myocardial infarction.","date":"2026","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/42056214","citation_count":0,"is_preprint":false},{"pmid":"42025389","id":"PMC_42025389","title":"Gut microbiota-derived trimethylamine-N-oxide protects pulmonary vascular barrier integrity via Vav guanine nucleotide exchange factor 3 (VAV3)-mediated cytoskeletal remodelling in acute lung injury.","date":"2026","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/42025389","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.23.682825","title":"Systemic infections alter cortical transcriptionalsignatures in Alzheimer’s disease","date":"2025-10-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.23.682825","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50508,"output_tokens":10962,"usd":0.157977,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21724,"output_tokens":7491,"usd":0.147948,"stage2_stop_reason":"end_turn"},"total_usd":0.305925,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"Vav3 functions as a GDP-GTP nucleotide exchange factor for RhoA, RhoG, and (to a lesser extent) Rac1; it binds physically to the nucleotide-free states of these GTPases. This activity is stimulated by tyrosine phosphorylation and becomes constitutively active upon deletion of the calponin-homology (CH) region. The DH and ZF domains are both essential for GTPase binding and activation, with the ZF region working coordinately with the catalytic DH region.\",\n      \"method\": \"Nucleotide exchange assays, physical binding assays, deletion/loss-of-function mutagenesis, actin cytoskeleton readouts in transfected cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro exchange assays combined with domain mutagenesis and multiple orthogonal functional readouts in a single foundational study\",\n      \"pmids\": [\"10523675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Expression of activated (N-terminally truncated) Vav3 induces actin relocalization, stress fibers, lamellipodia, membrane ruffles, and cytokinesis defects (binucleated cells), requiring only the DH-PH-ZF central region and not the C-terminal SH3-SH2-SH3 domains.\",\n      \"method\": \"Truncation mutant overexpression, fluorescence microscopy of actin cytoskeleton, cytokinesis assay in transfected cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — domain dissection with multiple cytoskeletal readouts, replicated in subsequent studies\",\n      \"pmids\": [\"10523675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Vav3 interacts with and is tyrosine-phosphorylated downstream of multiple receptor protein tyrosine kinases (EGFR, Ros, insulin receptor, IGF-IR); it also associates with downstream signaling molecules Shc, Grb2, PLC-γ, and PI3K. Overexpression activates Rac1 and Cdc42, while N-terminal truncation (removing CH and acidic domains) activates RhoA and Rac1 but loses Cdc42 activation.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, in vitro GST-fusion binding assays for active GTPases, transfection in 293T and NIH 3T3 cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple binding assays, GTPase activation assays, domain mutagenesis, replicated across labs\",\n      \"pmids\": [\"11094073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Vav3 expression is cell-cycle regulated, being transiently up-regulated during mitosis in HeLa cells. Enforced Vav3 expression perturbs cytokinesis and produces multinucleated cells in a RhoA-dependent manner requiring phosphorylation of the regulatory tyrosine Y173.\",\n      \"method\": \"Cell cycle synchronization, Western blot, enforced expression, RhoA dependence assay, dominant-negative and phosphorylation-site mutant analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean cell-cycle and loss-of-function experiments with mutagenesis of the key regulatory tyrosine\",\n      \"pmids\": [\"11917103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Vav3-induced cell transformation (focus formation) requires PI3K/Akt signaling, Rac1, RhoA, and Cdc42, but PI3K/MAPK inhibition does not affect cytoskeletal (lamellipodia/filopodia) changes. Cell motility enhancement depends on PI3K, Rac1, and Cdc42 but not RhoA.\",\n      \"method\": \"Focus-formation assays, pharmacological inhibition of PI3K/MAPK, dominant-negative GTPase constructs, cell motility assays in NIH 3T3 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — epistasis via dominant-negative constructs and pharmacological inhibitors with multiple orthogonal readouts\",\n      \"pmids\": [\"11884391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The adaptor protein APS binds the N-terminal CH (autoinhibitory) domain of Vav3. This interaction is stabilized by Lck-mediated tyrosine phosphorylation of Vav3, and APS in turn enhances Lck-mediated Vav3 phosphorylation. APS binding to the PH domain of APS–Vav3 CH domain interaction relieves autoinhibition and increases Vav3 transforming activity.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, focus-formation assays, domain mutant analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding and functional assays in single lab\",\n      \"pmids\": [\"12400014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"In B cells, Vav3 promotes sustained PIP3 production via Rac1 activation of PI3K, downstream of BCR engagement. Loss of Vav3 attenuates PIP3 generation, calcium mobilization, and JNK activation; these defects are rescued by deletion of the PIP3 phosphatase SHIP.\",\n      \"method\": \"B cell line Vav3 knockout, dominant-negative Rac1 expression, PI3K activity assay, PIP3 measurement, SHIP deletion rescue\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function, biochemical pathway rescue, multiple readouts confirming pathway position\",\n      \"pmids\": [\"11805146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Vav1 and Vav3 have redundant roles in activating PLCγ2 downstream of the ITAM-coupled collagen receptor GPVI in platelets. Single Vav3 knockout shows normal GPVI response; Vav1/Vav3 double knockout markedly inhibits aggregation, spreading, and PLCγ2 tyrosine phosphorylation upon GPVI stimulation.\",\n      \"method\": \"Single and double gene knockout in mice, platelet aggregation assay, spreading assay, Western blot for PLCγ2 phosphorylation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic epistasis with double knockout and multiple functional platelet readouts\",\n      \"pmids\": [\"15456756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Vav3 is essential for stimulated osteoclast activation in vivo: Vav3-deficient osteoclasts display defective actin cytoskeleton organization, polarization, spreading, and bone resorption due to impaired signaling downstream of M-CSF receptor and αvβ3 integrin. Genetic and biochemical evidence places Syk tyrosine kinase as a crucial upstream regulator of Vav3 in osteoclasts.\",\n      \"method\": \"Vav3 knockout mice, bone density measurement, osteoclast functional assays, Syk genetic and biochemical epistasis, co-immunoprecipitation\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout with bone density phenotype, biochemical pathway placement, multiple orthogonal methods\",\n      \"pmids\": [\"15711558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"During NGF-stimulated neurite outgrowth in PC12 cells, local PIP3 accumulation recruits Vav2 and Vav3 to activate Rac1 and Cdc42. Vav2/Vav3 are required for a positive feedback loop between PI3K and Rac1/Cdc42 that drives localized protrusions; RNAi depletion of Vav2 and Vav3 significantly inhibits Rac1/Cdc42 activation and neurite formation.\",\n      \"method\": \"FRET biosensors, RNAi knockdown, live-cell imaging of PIP3 and GTPase activity in PC12 cells\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — FRET activity imaging plus RNAi knockdown with multiple functional readouts in a single rigorous study\",\n      \"pmids\": [\"15728722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TCR-induced membrane translocation and immunological synapse (IS) recruitment of Vav3 requires its SH2 domain-mediated association with SLP-76. Vav3 mutants with disabled SH2 (R697L) or lacking SH3-SH2-SH3 domains fail to bind SLP-76 and do not translocate. Membrane localization depends on upstream signaling via Lck, ZAP-70, LAT, and SLP-76. Vav3 is required for NFAT activation in T cells lacking Vav1.\",\n      \"method\": \"Subcellular localization imaging (membrane/IS), Vav3 mutant expression, co-immunoprecipitation with SLP-76, signaling-deficient cell lines (Lck−/−, ZAP-70−/−, LAT−/−, SLP-76−/−), NFAT reporter assay, Vav3 knockdown in Vav1-deficient T cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including domain mutagenesis, deficient cell lines, and localization/functional assays\",\n      \"pmids\": [\"15708849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Single-particle electron microscopy resolved the structures of inactive (unphosphorylated), active (tyrosine-phosphorylated), and constitutively active (N-terminally deleted) Vav3. Tyrosine phosphorylation induces global conformational rearrangements; the phosphorylated and N-terminally deleted forms have distinct conformations, indicating that constitutive oncogenic activity is structurally more complex than simple relief of autoinhibition.\",\n      \"method\": \"Single-particle electron microscopy, structural comparison of three functional states\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural method with functional state comparison, single lab but rigorous EM-based analysis\",\n      \"pmids\": [\"15775967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Vav3 potentiates androgen receptor (AR) transcriptional activity in a GEF-independent but pleckstrin homology (PH) domain-dependent manner. Vav3 does not directly interact with AR and does not increase AR protein levels; enhancement of AR activity requires the AR N-terminal activation function 1 (AF1).\",\n      \"method\": \"Reporter gene assays, Vav3 knockdown, domain deletion mutants, co-immunoprecipitation (negative result for direct AR interaction)\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assays with domain dissection, single lab; direct binding was negative\",\n      \"pmids\": [\"16384856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Vav3 deficiency in mice causes tachycardia, systemic hypertension, and cardiovascular remodeling via sympathetic neuron hyperactivity from birth, leading to elevated catecholamines, renin-angiotensin system activation, and progressive loss of cardiovascular homeostasis. Pharmacological studies confirmed the causative hierarchy of sympathetic → renin-angiotensin events.\",\n      \"method\": \"Vav3 knockout mice, blood pressure and heart rate measurement, catecholamine assays, pharmacological blockade of sympathetic and renin-angiotensin systems\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout with pharmacological rescue establishing pathway hierarchy\",\n      \"pmids\": [\"16767097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Vav3 is overexpressed in androgen-independent prostate cancer; its DH domain is responsible for AR activation. Vav3 overexpression activates AR via the PI3K-Akt pathway; PI3K inhibitors or dominant-negative Akt attenuate this effect, and PI3K co-transfection enhances it.\",\n      \"method\": \"siRNA knockdown, overexpression, AR luciferase reporter assay, PI3K inhibition, dominant-negative Akt, Western blot for pAkt\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple signaling assays with domain dissection, single lab\",\n      \"pmids\": [\"16762975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In NPM-ALK+ anaplastic large cell lymphoma, Vav3 is activated by NPM-ALK and mediates Rac1 activation downstream. Vav3 associates with NPM-ALK via its SH2 domain binding to phospho-Y343 of NPM-ALK, forming a complex with pp60c-src and Lyn. Src kinases control Vav3/Rac1 stimulation. Vav3-specific shRNA and dominant-negative Rac1 inhibit NPM-ALK-induced cell motility and invasion.\",\n      \"method\": \"Co-immunoprecipitation, domain mutant analysis (SH2-disabled), shRNA knockdown, dominant-negative Rac1, motility/invasion assays, phospho-Vav3 in patient biopsies\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, domain mapping, shRNA loss-of-function, and in vivo patient biopsy validation in a single study\",\n      \"pmids\": [\"17998938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Vav3 complexes physically with ERα (demonstrated by GST pulldown). The DH domain of Vav3 is essential for ERα activation. Vav3 activates ERα partly via the PI3K-Akt pathway and stimulates breast cancer cell growth.\",\n      \"method\": \"GST pulldown, luciferase reporter assay, siRNA knockdown, PI3K inhibition, domain deletion analysis\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — GST pulldown for physical interaction plus functional reporter assays with domain dissection, single lab\",\n      \"pmids\": [\"18518979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"AhR directly regulates constitutive Vav3 mRNA expression in a ligand-independent manner by binding to the vav3 promoter. In AhR-null fibroblasts, reduced Vav3 expression leads to decreased Rac1 activity, increased RhoA/ROCK pathway activation, enlarged cell area with increased F-actin stress fibers, depolarized focal adhesions, and enhanced spreading/adhesion. Re-expression of AhR or Vav3 restores wild-type morphology.\",\n      \"method\": \"ChIP of AhR at vav3 promoter, AhR-/- and Vav3-/- MEFs, pharmacological Rac1/ROCK inhibition, siRNA knockdown of Vav3, GTPase activity assays, cell morphology and adhesion assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP confirms transcriptional regulation; multiple genetic and pharmacological rescue experiments with orthogonal readouts\",\n      \"pmids\": [\"19158396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Aryl hydrocarbon receptor (Ahr) controls Vav3 expression in kidney, lung, heart, liver, and brainstem in a ligand-independent manner. Ahr-/- and Vav3-/- mice share phenotypes of hypertension, tachypnea, and sympathoexcitation, with Ahr-/- mice also showing GABAergic transmission defects in the ventrolateral medulla present in Vav3-/- mice.\",\n      \"method\": \"Ahr-/- and Vav3-/- mouse phenotypic comparison, tissue Vav3 expression analysis, Ahr ligand treatment, cardiorespiratory and autonomic measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — parallel genetic knockout comparison in multiple tissues with overlapping phenotypes establishes in vivo pathway hierarchy\",\n      \"pmids\": [\"21115475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Vav3 localizes to both cytoplasm and nucleus; nuclear localization depends on the PH domain. Membrane targeting of Vav3 abolishes its potentiation of AR activity, while nuclear targeting of a PH mutant rescues AR coactivation. Sequential ChIP shows Vav3 and AR are co-recruited to the same AR target gene enhancer complexes. Vav3 strongly stimulates AR N-terminal–C-terminal (N-C) interaction required for maximal AR transcriptional activity.\",\n      \"method\": \"Subcellular fractionation, fluorescence localization, membrane/nuclear targeting constructs, sequential ChIP (re-ChIP), N-C interaction assay, luciferase reporter assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP and re-ChIP combined with localization experiments and multiple functional assays in a single study\",\n      \"pmids\": [\"21765461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Vav3 physically interacts with AR splice variant AR3 (AR-V7) as shown by co-immunoprecipitation. Vav3 potently enhances transcriptional activity of AR3 and ARv567es, and promotes nuclear accumulation of AR3. Vav3 or AR3 knockdown greatly reduces CRPC cell proliferation and ligand-independent AR activity.\",\n      \"method\": \"Co-immunoprecipitation, nuclear/total AR3 fractionation, siRNA knockdown, luciferase reporter assay, soft agar colony formation\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus functional assays with knockdown, multiple orthogonal readouts\",\n      \"pmids\": [\"23023561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Vav3 deficiency delays p190-BCR-ABL-driven B-cell lymphoblastic leukemogenesis and phenocopies Rac2 deficiency (a downstream effector), establishing Rac2 as a downstream effector of Vav3 in this context. Vav3 deficiency induces apoptosis of leukemic progenitors with decreased RhoGTPase/PAK activation, increased Bad phosphorylation, and upregulation of Bax, Bak, and Bik. Vav3 activity is only partly ABL TK-dependent, and Vav3 deficiency collaborates with TKIs to inhibit CrkL activation.\",\n      \"method\": \"Vav3 knockout and Vav1/Vav2-deficient mouse models, BCR-ABL leukemogenesis assay, apoptosis assays, GTPase activation assays, TKI combination studies in vitro and in vivo\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with multiple knockouts, biochemical pathway analysis, in vivo leukemogenesis model\",\n      \"pmids\": [\"22692505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"EphA2 stimulation by ephrinA1 recruits and tyrosine-phosphorylates Vav3, leading to Rac1 activation and increased prostate cancer cell migration and invasion. Reduction of Vav3 decreases para-aortic lymph node and bone metastasis in vivo.\",\n      \"method\": \"Receptor stimulation, co-immunoprecipitation, Rac1 activity assay, Vav3 knockdown, in vivo metastasis model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and GTPase assay with in vivo validation, single lab\",\n      \"pmids\": [\"22659453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Co-chaperone Cdc37 was identified as a Vav3-interacting protein by yeast two-hybrid and confirmed by GST pulldown and co-immunoprecipitation. Cdc37 potentiates Vav3 co-activation of AR transcriptional activity and enhances AR N-C interaction. Disruption of Vav3-Cdc37 interaction inhibits Vav3 enhancement of AR activity and reduces prostate cancer cell proliferation in Vav3-expressing cells. Cdc37 does not affect Vav3 nucleotide exchange activity, protein levels, or subcellular localization.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, AR reporter assay, AR N-C interaction assay, cell proliferation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple binding assays plus functional validation, single lab\",\n      \"pmids\": [\"23281476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"VAV3 depletion comparatively reduces viability of endocrine-therapy-resistant breast cancer cell models. VAV3 expression is selectively reduced upon ERα depletion or by the compound YC-1, placing VAV3 downstream of ERα in endocrine-resistant breast cancer signaling.\",\n      \"method\": \"shRNA-mediated VAV3 depletion, ERα depletion, viability assays, gene expression analysis\",\n      \"journal\": \"Breast cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — shRNA loss-of-function with ERα depletion epistasis, single lab\",\n      \"pmids\": [\"24886537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRAF6's coiled-coil domain directly interacts with the DH domain of Vav3, forming a complex within the RANK signaling complex independent of the TRAF6 ubiquitination pathway. This TRAF6-Vav3 interaction results from cross-talk between TRAF6-binding sites (T6BSs) and the IVVY motif in the RANK cytoplasmic tail, and enhances downstream NF-κB, MAPK, and NFATc1 activation, thereby inducing osteoclastogenesis.\",\n      \"method\": \"Proteomic screen for TRAF6-interacting proteins, co-immunoprecipitation, domain-specific interaction mapping, RANK cytoplasmic tail mutants, NF-κB/MAPK/NFATc1 signaling assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — proteomic identification confirmed by Co-IP with domain mapping and multiple functional signaling readouts\",\n      \"pmids\": [\"27507811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DNMT3B overexpression in HaCaT cells downregulates VAV3 expression via promoter methylation of the VAV3 gene, establishing DNMT3B as a methyltransferase writer that epigenetically represses VAV3.\",\n      \"method\": \"DNMT3B overexpression, gene expression microarray, promoter methylation analysis\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — epigenetic regulation shown by single method (methylation analysis), single lab\",\n      \"pmids\": [\"28123849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The atypical C1 domain of Vav3 lacks phorbol ester/diacylglycerol binding (analogous to Vav1) due to specific residues. Engineering phorbol ester binding into the modified Vav3 C1 domain disrupts its guanyl nucleotide exchange activity and causes membrane localization upon phorbol ester treatment, accompanied by altered interactions with other signaling proteins.\",\n      \"method\": \"Mutagenesis of C1 domain, phorbol ester binding assay, GEF activity assay, subcellular localization analysis, co-immunoprecipitation of signaling partners\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Weak — in vitro GEF assay and mutagenesis plus localization, single lab without replication\",\n      \"pmids\": [\"28927664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Vav3 is exclusively expressed in microvascular endothelial cells and is associated with a high-resistance barrier phenotype. The barrier-enhancing effect of Vav3 requires its DH domain and downstream activation of Rap1. Vav3 inactivation in vivo increases vascular leakage, establishing Vav3 as a regulator of endothelial barrier stability via DH-domain-dependent Rap1 activation.\",\n      \"method\": \"Endothelial cell gene expression correlation, ectopic Vav3 expression, DH domain mutant, Rap1 activation assay, barrier resistance measurement, in vivo Vav3 inactivation/vascular permeability assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro domain dissection and Rap1 epistasis combined with in vivo vascular permeability phenotype\",\n      \"pmids\": [\"29858212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Vav3 controls vascular smooth muscle cell (VSMC) proliferation and migration through Rac1/PAK signaling. Vav3 catalytic activity (GEF function) is required for its effect on proliferation; co-expression of dominant-negative Rac1-N17 blocks the proliferative effect. Vav3 overexpression induces Rac1 membrane enrichment and PAK activation.\",\n      \"method\": \"siRNA silencing screen of 27 Rho GEFs, Vav3 overexpression and catalytic mutant, dominant-negative Rac1, PAK activation assay, proliferation/migration assays, in vivo stented artery model\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional screen, catalytic mutant epistasis, dominant-negative GTPase, and in vivo validation\",\n      \"pmids\": [\"19969623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Phosphorylation of Tyr426 (equivalent site) in chicken 3BP2 by Syk is required for the inducible interaction of 3BP2 with the SH2 domain of Vav3. Loss of this phosphorylation reduces BCR-mediated Rac1 activation, placing 3BP2-Vav3 interaction as a link between Syk and Rac1 activation.\",\n      \"method\": \"Mutational analysis of 3BP2 phospho-sites, co-immunoprecipitation with Vav3 SH2 domain, Rac1 activation assay in DT40 B cells\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-directed mutagenesis with functional Rac1 readout, confirmed in chicken B cell model\",\n      \"pmids\": [\"24406398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In the context of oligodendrocyte biology, Vav3 deficiency accelerates OPC differentiation toward mature oligodendrocytes but reduces myelination capacity; remyelination is impaired in Vav3 knockout cerebellar slices and cuprizone-lesioned mice. FRET biosensors reveal altered RhoA GTPase activation profile in Vav3-deficient oligodendrocytes.\",\n      \"method\": \"Vav3 knockout mice, OPC differentiation assay, myelination of synthetic microfibers, lysolecithin demyelination of cerebellar slices, cuprizone model, FRET-based Rho GTPase biosensors\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple in vitro and in vivo myelination models plus FRET-based mechanistic readout\",\n      \"pmids\": [\"30450647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ERBB4 interacts with VAV3 via its kinase activity and phosphorylation of Tyr-1022 and Tyr-1162, with the intact VAV3 SH2 domain required for binding. ERBB4 stimulates tyrosine phosphorylation of the VAV3 activation domain (required for GEF activity). Active VAV3 mediates ERBB4-stimulated breast cancer cell migration. VAV1 and VAV2 also co-precipitate with ERBB4.\",\n      \"method\": \"MS-based interactome analysis, targeted MS, co-immunoprecipitation, ERBB4 kinase mutants, ERBB4 phospho-site mutants, SH2 domain mutant VAV3, dominant-negative VAV3, shRNA knockdown, migration assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — MS identification confirmed by Co-IP, domain mapping with mutagenesis of both partners, and functional migration assays\",\n      \"pmids\": [\"32561640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Vav3 is apically overexpressed in cystic fibrosis (CF) airway epithelial cells, associates with active β1 integrin luminally exposed, and increases fibronectin deposition. These luminal Vav3/β1-integrin/fibronectin microdomains mediate enhanced Pseudomonas aeruginosa adhesion to the CF epithelium. Vav3 inhibition normalizes fibronectin/β1-integrin expression, improves CF epithelial integrity, and prevents bacterial trapping.\",\n      \"method\": \"RNA-seq, functional overexpression and siRNA knockdown, co-localization imaging, bacterial adhesion assay, fibronectin/integrin expression analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain- and loss-of-function with mechanistic dissection of β1-integrin/fibronectin complex formation and bacterial adhesion readout\",\n      \"pmids\": [\"32640241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The small molecule IODVA1 binds directly to VAV3 and inhibits RAC activation and downstream signaling. In Vav3-null cells and animals, IODVA1 shows no activity, confirming VAV3 as its specific target. IODVA1 inhibits BCR-ABL1-driven leukemia cell proliferation and survival in a VAV3-dependent manner, overcoming TKI resistance.\",\n      \"method\": \"Small-molecule binding to VAV3, Vav3-null genetic control, RAC activation assay, BCR-ABL1 leukemia models in vitro and in vivo, patient-derived xenografts\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct small-molecule binding to VAV3 with null-cell genetic validation and multiple in vitro/in vivo models\",\n      \"pmids\": [\"34711926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In BCR-ABL B-ALL, Vav3 translocates predominantly to the nucleus where it interacts with BCR-ABL, Rac, and PRC1 proteins Bmi1, Ring1b, and Ezh2. The GEF activity of Vav3 is required for Bmi1-dependent B-cell progenitor self-renewal, nuclear Rac activation, interaction with Bmi1, and mono-ubiquitination of H2A(K119). Mechanistically, nuclear Vav3 prevents Phlpp2-sensitive Akt(S473)-dependent phosphorylation of Bmi1 at S314, which promotes leukemic B-cell progenitor transcriptional reprogramming.\",\n      \"method\": \"Nuclear fractionation, co-immunoprecipitation of nuclear Vav3 complexes, GEF-dead mutant functional assays, H2AK119Ub ChIP, Akt/Phlpp2/Bmi1 phosphorylation analysis, proliferation and self-renewal assays in Vav3-null leukemia model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (nuclear Co-IP, ChIP, mutagenesis, phosphorylation analysis) establishing a non-canonical nuclear GEF mechanism\",\n      \"pmids\": [\"35650206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HuR accumulates in the cytoplasm of CF airway epithelial cells, binds to and stabilizes Vav3 mRNA, causing Vav3 overexpression. Disruption of the HuR-Vav3 mRNA interaction improves CF epithelial integrity, inhibits fibronectin-based bacterial docking platforms, and prevents P. aeruginosa adhesion.\",\n      \"method\": \"RNA-seq, RIP (RNA immunoprecipitation) for HuR-Vav3 mRNA binding, HuR-Vav3 interaction disruption, epithelial integrity and bacterial adhesion assays\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP confirms mRNA-protein interaction; functional rescue provides mechanistic link, single lab\",\n      \"pmids\": [\"36602863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DDX5 binds VAV3 mRNA and facilitates its N6-methyladenosine (m6A) modification by interacting with the methyltransferase METTL3; m6A-modified VAV3 mRNA is then recognized by IGF2BP1, increasing mRNA stability and VAV3 expression in esophageal squamous cell carcinoma.\",\n      \"method\": \"RIP for DDX5-VAV3 mRNA binding, METTL3 interaction assays, m6A modification of VAV3 mRNA, IGF2BP1 recognition of m6A-VAV3, mRNA stability assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-protein binding assays and m6A modification cascade, single lab\",\n      \"pmids\": [\"39289531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"STAT3 activation by high-fat diet (HFD) acts as a transcriptional factor to suppress VAV3 expression in liver. VAV3 deficiency retards GLUT4 membrane translocation and impairs glucose homeostasis; VAV3 also participates in cholesterol metabolism in hepatocytes. rAAV8-mediated VAV3 overexpression improves glucose homeostasis and attenuates hepatic cholesterol accumulation in HFD-fed mice.\",\n      \"method\": \"HFD mouse model, STAT3 transcriptional assay, GLUT4 vesicle trafficking assay, glucose uptake/homeostasis measurements, VAV3 rescue by rAAV8 vector\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo rescue and mechanistic GLUT4 trafficking data, single lab\",\n      \"pmids\": [\"38617550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Bcl11a directly regulates Vav3 as a downstream transcriptional target in cerebellar Purkinje cells. Conditional Bcl11a deletion reduces Vav3 expression, and Vav3 overexpression partially rescues Purkinje cell dysfunction, dendritic morphology, and abnormal motor/social behaviors in Bcl11a-deficient mice.\",\n      \"method\": \"Conditional Purkinje cell-specific Bcl11a knockout, Vav3 overexpression rescue, behavioral assays (motor, social), electrophysiology, dendritic morphology analysis\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with rescue experiment demonstrating Vav3 as a functional downstream target of Bcl11a in vivo\",\n      \"pmids\": [\"40855003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Spleen tyrosine kinase (SYK) promotes Vav3 phosphorylation in osteoclasts; SYK and Vav3 colocalize at the leading edge of osteoclasts. SYK knockdown reduces Vav3 phosphorylation, abolishes SYK/Vav3 enrichment at the leading edge, decreases actin ring formation, and attenuates bone resorption.\",\n      \"method\": \"Co-localization imaging, SYK knockdown, Western blot for p-Vav3, bone resorption lacunae assay, actin ring formation assay, ACPA+ IgG stimulation of osteoclasts\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-localization and loss-of-function with multiple osteoclast readouts; single lab, single study\",\n      \"pmids\": [\"40787875\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"VAV3 is a tyrosine phosphorylation-regulated GDP-GTP exchange factor (GEF) that activates RhoA, RhoG, Rac1, and Cdc42 via its catalytic DH domain working cooperatively with the ZF domain; activation is governed by global conformational changes triggered by phosphorylation of a key regulatory tyrosine (Y173) that relieves CH-domain autoinhibition, and VAV3 is recruited to activated receptor tyrosine kinases (EGFR, Ros, IR, IGF-IR, EphA2, ERBB4) and immune-receptor complexes (via SH2-domain binding to phospho-SLP-76 and phospho-3BP2) to drive actin cytoskeletal reorganization, cell migration, cytokinesis, and specialized functions in osteoclasts (downstream of Syk and αvβ3 integrin), endothelial barrier integrity (via Rap1), and B-cell signaling (sustaining PIP3/PI3K–Rac1 positive feedback); in the nucleus, VAV3 acts as a GEF-activity-dependent co-activator of PRC1 (interacting with Bmi1, Ring1b, Ezh2) and, in a GEF-independent but PH-domain-dependent manner, as a co-activator of androgen receptor (AR) and estrogen receptor (ERα) by promoting AR N-C interaction and chromatin recruitment; VAV3 expression is transcriptionally controlled by the aryl hydrocarbon receptor (AhR) and BCL11A, and post-transcriptionally stabilized by HuR binding to its mRNA and by DDX5/METTL3-mediated m6A modification recognized by IGF2BP1.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"VAV3 is a tyrosine phosphorylation-regulated guanine nucleotide exchange factor (GEF) that activates the Rho-family GTPases RhoA, RhoG, Rac1, and Cdc42 to drive actin cytoskeletal reorganization, cell migration, and cytokinesis [#0, #1, #2]. Catalysis requires the DH domain working coordinately with the adjacent ZF region, and basal activity is held in check by the N-terminal calponin-homology (CH) domain whose deletion renders VAV3 constitutively active [#0]; tyrosine phosphorylation drives global conformational rearrangements that distinguish inactive, phosphorylated, and oncogenically truncated states [#11]. VAV3 is recruited to and phosphorylated downstream of multiple receptor tyrosine kinases—EGFR, Ros, the insulin receptor, IGF-IR, EphA2, and ERBB4—and of oncogenic fusion kinases such as NPM-ALK, binding their phosphotyrosines through its SH2 domain to couple receptor activation to Rac1-driven motility and invasion [#2, #15, #22, #32]. In immune-receptor signaling, the SH2 domain links VAV3 to phospho-SLP-76 at the immunological synapse and to Syk-phosphorylated 3BP2, positioning it downstream of antigen and ITAM receptors to support Rac1 activation, NFAT signaling, and a Rac1–PI3K positive feedback loop that sustains PIP3 generation in B cells [#6, #10, #30]. VAV3 executes specialized GTPase-dependent programs in distinct tissues: it is essential for osteoclast actin organization and bone resorption downstream of Syk, the M-CSF receptor, αvβ3 integrin, and TRAF6/RANK [#8, #25, #40]; it maintains endothelial barrier integrity via DH-domain-dependent Rap1 activation [#28]; and it regulates vascular smooth muscle proliferation through Rac1/PAK [#29] and oligodendrocyte myelination through RhoA [#31]. Beyond cytoplasmic GTPase signaling, VAV3 acts in the nucleus: in a GEF-independent, PH-domain-dependent manner it co-activates androgen and estrogen receptors by promoting AR N–C interaction and chromatin co-recruitment [#12, #19, #16], while in BCR-ABL leukemia its nuclear GEF activity drives PRC1-dependent H2AK119 mono-ubiquitination and Bmi1-dependent progenitor self-renewal [#35, #21]. VAV3 expression is controlled transcriptionally by the aryl hydrocarbon receptor and BCL11A [#17, #18, #39] and post-transcriptionally stabilized by HuR and by m6A modification, contributing to disease phenotypes including cystic fibrosis airway pathology and cancer [#36, #37, #33]. Loss of VAV3 in mice causes sympathetic hyperactivity, hypertension, and cardiovascular remodeling [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established VAV3's core biochemical identity by showing it is a Rho-family GEF whose catalytic DH domain works with the ZF region and is held autoinhibited by the CH domain.\",\n      \"evidence\": \"in vitro nucleotide exchange assays, GTPase binding, and CH-deletion mutagenesis with actin cytoskeleton readouts in transfected cells\",\n      \"pmids\": [\"10523675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GTPase preference (RhoA/RhoG vs Rac1/Cdc42) varied with construct\", \"physiological trigger of phosphorylation not defined in this study\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Connected VAV3 to receptor tyrosine kinase signaling, showing it is phosphorylated downstream of EGFR/Ros/IR/IGF-IR and links to Shc, Grb2, PLC-γ, and PI3K.\",\n      \"evidence\": \"yeast two-hybrid, co-IP, GST-fusion GTPase activation assays, domain mutagenesis in 293T/NIH 3T3 cells\",\n      \"pmids\": [\"11094073\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"direct vs adaptor-mediated receptor binding not fully resolved\", \"cell-type specificity of GTPase output unaddressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined VAV3 regulation of cytokinesis and transformation, identifying the Y173 regulatory tyrosine and the PI3K/Akt–Rac1/RhoA/Cdc42 requirements for transforming and motility activity.\",\n      \"evidence\": \"cell-cycle synchronization, focus-formation and motility assays, phospho-site and dominant-negative GTPase mutants\",\n      \"pmids\": [\"11917103\", \"11884391\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"mechanism coupling cytokinesis to RhoA not detailed\", \"physiological role of mitotic upregulation unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed VAV3 sustains PIP3/PI3K–Rac1 feedback in B-cell receptor signaling, positioning it as an amplifier of lipid second messengers.\",\n      \"evidence\": \"B-cell knockout, dominant-negative Rac1, PIP3/PI3K assays, SHIP-deletion rescue\",\n      \"pmids\": [\"11805146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"direct PI3K activation mechanism by Rac1 not structurally defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Established functional redundancy of VAV3 with VAV1 in ITAM/GPVI signaling, explaining mild single-knockout phenotypes.\",\n      \"evidence\": \"single and double knockout mice, platelet aggregation/spreading and PLCγ2 phosphorylation assays\",\n      \"pmids\": [\"15456756\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"non-redundant VAV3-specific roles in platelets not identified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Resolved the conformational basis of VAV3 activation, showing phosphorylation drives global rearrangements distinct from N-terminal truncation.\",\n      \"evidence\": \"single-particle electron microscopy of three functional states\",\n      \"pmids\": [\"15775967\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"atomic-resolution structure absent\", \"dynamics of intermediate states not captured\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Placed VAV3 in immune-receptor and osteoclast pathways, linking SH2-mediated SLP-76 binding to synapse recruitment and Syk/integrin signaling to bone resorption.\",\n      \"evidence\": \"SH2-domain mutants, signaling-deficient cell lines, NFAT reporter, Vav3-knockout osteoclast assays, bone density measurement\",\n      \"pmids\": [\"15708849\", \"15711558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"how distinct receptors select VAV3 GTPase output not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed VAV3 couples local PIP3 to Rac1/Cdc42 feedback for directed protrusion during neurite outgrowth, generalizing the lipid-feedback mechanism.\",\n      \"evidence\": \"FRET biosensors and RNAi in PC12 cells\",\n      \"pmids\": [\"15728722\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"VAV2 vs VAV3 specific contributions not separated\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed a non-canonical, GEF-independent nuclear receptor co-activator role: VAV3 potentiates AR via its PH domain without direct binding or AF1-independent mechanisms.\",\n      \"evidence\": \"AR reporter assays, PH/domain deletions, co-IP (negative for direct AR binding)\",\n      \"pmids\": [\"16384856\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"intermediary linking VAV3 to AR not identified here\", \"single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Linked VAV3 to androgen-independent prostate cancer and to AR activation through the DH domain and PI3K-Akt pathway, partially reconciling GEF and co-activator roles.\",\n      \"evidence\": \"knockdown/overexpression, AR reporter, PI3K inhibition, dominant-negative Akt\",\n      \"pmids\": [\"16762975\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"reconciliation of DH-dependent vs GEF-independent AR activation incomplete\", \"single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated a physiological in vivo role: VAV3 loss causes sympathetic hyperactivity, hypertension, and cardiovascular remodeling.\",\n      \"evidence\": \"knockout mice, blood pressure/catecholamine measurement, pharmacological pathway dissection\",\n      \"pmids\": [\"16767097\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"cell-autonomous neuronal mechanism of VAV3 in sympathetic neurons not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified AhR as a ligand-independent transcriptional regulator of VAV3 controlling Rac1/RhoA balance and cell morphology.\",\n      \"evidence\": \"ChIP at vav3 promoter, AhR-/- and Vav3-/- MEFs, rescue, GTPase activity and morphology assays\",\n      \"pmids\": [\"19158396\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"AhR target-gene context beyond vav3 not mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended GEF function to vascular smooth muscle proliferation/migration via Rac1/PAK, confirming catalytic dependence in vivo.\",\n      \"evidence\": \"RhoGEF siRNA screen, catalytic mutant, dominant-negative Rac1, PAK assay, stented artery model\",\n      \"pmids\": [\"19969623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"upstream receptor driving VSMC VAV3 activation not specified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Confirmed the AhR–VAV3 axis in vivo across tissues, showing overlapping cardiorespiratory and autonomic phenotypes.\",\n      \"evidence\": \"parallel Ahr-/- and Vav3-/- mouse phenotyping across multiple organs\",\n      \"pmids\": [\"21115475\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"molecular link from VAV3 to GABAergic transmission unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Resolved the nuclear AR co-activation mechanism: PH-dependent nuclear localization enables VAV3/AR co-recruitment to enhancers and stimulation of AR N–C interaction.\",\n      \"evidence\": \"fractionation, nuclear/membrane targeting constructs, sequential ChIP, N-C interaction and reporter assays\",\n      \"pmids\": [\"21765461\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"chromatin-associated VAV3 binding partners incompletely defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Connected VAV3 to RTK and fusion-kinase-driven cancer (EphA2, NPM-ALK) and to AR splice-variant-driven CRPC, broadening its oncogenic SH2-coupled signaling.\",\n      \"evidence\": \"co-IP, SH2 domain mapping, Rac1 assays, shRNA, AR-V7/ARv567es reporter assays, in vivo metastasis models\",\n      \"pmids\": [\"22659453\", \"17998938\", \"23023561\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"relative weighting of GEF vs scaffolding contributions in tumors varies by study\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined VAV3's role in BCR-ABL leukemogenesis with Rac2 as a downstream effector and identified Cdc37 as a co-activator partner for AR signaling.\",\n      \"evidence\": \"multiple Vav-knockout leukemia models, apoptosis/GTPase assays, TKI combinations; yeast two-hybrid and Co-IP for Cdc37\",\n      \"pmids\": [\"22692505\", \"23281476\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cdc37 mechanism on VAV3 conformation unknown (no effect on GEF activity/localization)\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Positioned VAV3 downstream of ERα in endocrine-resistant breast cancer survival and mapped the 3BP2–VAV3 SH2 link in BCR signaling.\",\n      \"evidence\": \"shRNA depletion with ERα epistasis; 3BP2 phospho-site mutagenesis and Rac1 assays in DT40 B cells\",\n      \"pmids\": [\"24886537\", \"24406398\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"direct vs indirect ERα–VAV3 regulation not resolved\", \"single-lab studies\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified a ubiquitination-independent TRAF6–VAV3 interaction within the RANK signaling complex driving osteoclastogenesis.\",\n      \"evidence\": \"proteomic screen, co-IP, domain mapping, RANK tail mutants, NF-κB/MAPK/NFATc1 assays\",\n      \"pmids\": [\"27507811\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"structural basis of TRAF6 coiled-coil/VAV3 DH contact undefined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Characterized atypical regulatory features—the non-DAG-binding C1 domain and DNMT3B-mediated promoter methylation—affecting VAV3 activity and expression.\",\n      \"evidence\": \"C1 domain mutagenesis with GEF/localization assays; DNMT3B overexpression with methylation analysis\",\n      \"pmids\": [\"28927664\", \"28123849\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"physiological relevance of C1 atypicality unclear\", \"DNMT3B regulation shown by single method\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined a DH-dependent Rap1 mechanism for VAV3 in endothelial barrier integrity and a RhoA-dependent role in oligodendrocyte myelination.\",\n      \"evidence\": \"endothelial DH mutant and Rap1 epistasis with in vivo permeability; Vav3-knockout myelination models with FRET RhoA biosensors\",\n      \"pmids\": [\"29858212\", \"30450647\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"how VAV3 selects Rap1 vs Rho-family output in different cells unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established ERBB4 as a VAV3-activating RTK in breast cancer migration and revealed VAV3's contribution to cystic fibrosis airway pathology via β1-integrin/fibronectin platforms for bacterial adhesion.\",\n      \"evidence\": \"MS interactome, ERBB4 kinase/phospho-site and VAV3 SH2 mutants, migration assays; RNA-seq, knockdown, co-localization, bacterial adhesion assays\",\n      \"pmids\": [\"32561640\", \"32640241\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GEF-dependence of CF integrin platform formation not fully dissected\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Validated VAV3 as a druggable target by identifying IODVA1, a direct binder that inhibits RAC activation and BCR-ABL1 leukemia in a VAV3-dependent manner.\",\n      \"evidence\": \"small-molecule binding, Vav3-null genetic control, RAC assays, leukemia models and PDX\",\n      \"pmids\": [\"34711926\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"binding site on VAV3 not structurally defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Uncovered a non-canonical nuclear GEF mechanism: VAV3 interacts with PRC1 (Bmi1, Ring1b, Ezh2) and drives H2AK119 mono-ubiquitination and Bmi1-dependent leukemic progenitor self-renewal.\",\n      \"evidence\": \"nuclear fractionation/Co-IP, GEF-dead mutants, H2AK119Ub ChIP, Akt/Phlpp2/Bmi1 phospho-analysis in Vav3-null leukemia\",\n      \"pmids\": [\"35650206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"how nuclear Rac activity feeds PRC1 mechanistically not fully resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established post-transcriptional control of VAV3 by HuR mRNA stabilization driving CF airway overexpression.\",\n      \"evidence\": \"RIP for HuR-Vav3 mRNA, interaction disruption, epithelial integrity and bacterial adhesion assays\",\n      \"pmids\": [\"36602863\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"signal triggering cytoplasmic HuR accumulation in CF not defined\", \"single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded VAV3 regulation to m6A modification (DDX5/METTL3/IGF2BP1) in carcinoma and revealed a STAT3-repressed metabolic role in hepatic glucose/cholesterol homeostasis.\",\n      \"evidence\": \"RIP, m6A modification and stability assays; HFD model, GLUT4 trafficking and glucose assays, rAAV8 rescue\",\n      \"pmids\": [\"39289531\", \"38617550\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"mechanism of VAV3 in GLUT4 trafficking and cholesterol metabolism not biochemically defined\", \"single labs\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified BCL11A as a transcriptional regulator of VAV3 in cerebellar Purkinje cells and refined the SYK–VAV3 osteoclast leading-edge mechanism.\",\n      \"evidence\": \"conditional Bcl11a knockout with Vav3 rescue and behavioral/electrophysiology readouts; SYK knockdown with co-localization, actin ring and bone resorption assays\",\n      \"pmids\": [\"40855003\", \"40787875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"direct vs indirect BCL11A regulation of vav3 promoter not shown\", \"SYK study single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How VAV3's distinct functional modes—cytoplasmic GTPase exchange, nuclear PRC1 co-activation, and GEF-independent nuclear receptor co-activation—are selected and integrated within a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"no unified model linking conformational state to nuclear vs cytoplasmic output\", \"atomic structures of active complexes lacking\", \"rules governing GTPase substrate selection across tissues undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005085\", \"supporting_discovery_ids\": [0, 2, 28, 29]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [12, 16, 19, 35]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 10, 32]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 19]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [19, 35]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 27, 33]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [1, 8, 40]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 6, 10, 32]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 7, 10, 30]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [12, 19, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [14, 21, 33, 35]}\n    ],\n    \"complexes\": [\"PRC1 (Bmi1/Ring1b/Ezh2)\", \"RANK-TRAF6 signaling complex\", \"NPM-ALK/Src/Lyn complex\"],\n    \"partners\": [\"SLP76\", \"TRAF6\", \"ERBB4\", \"EPHA2\", \"SH3BP2\", \"CDC37\", \"BMI1\", \"STAP2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}